

**Clinical trial results:****A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer****Summary**

EudraCT number	2015-003605-42
Trial protocol	ES RO BE LT SK PT HU AT LV FR NL HR IT
Global end of trial date	13 December 2022

Results information

Result version number	v4 (current)
This version publication date	22 November 2023
First version publication date	23 July 2020
Version creation reason	

Trial information**Trial identification**

Sponsor protocol code	GO29438
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02657434
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Hoffmann-La Roche
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland,
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 December 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	13 December 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of this study is to evaluate the efficacy and safety of atezolizumab in combination with carboplatin or cisplatin + pemetrexed compared with carboplatin or cisplatin+ pemetrexed in subjects who are chemotherapy-naive and have Stage IV non-squamous non-small cell lung cancer (NSCLC).

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 April 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 3
Country: Number of subjects enrolled	Australia: 25
Country: Number of subjects enrolled	Austria: 1
Country: Number of subjects enrolled	Belgium: 6
Country: Number of subjects enrolled	Bulgaria: 1
Country: Number of subjects enrolled	Chile: 12
Country: Number of subjects enrolled	Spain: 118
Country: Number of subjects enrolled	France: 47
Country: Number of subjects enrolled	United Kingdom: 40
Country: Number of subjects enrolled	Hungary: 17
Country: Number of subjects enrolled	Ireland: 2
Country: Number of subjects enrolled	Israel: 9
Country: Number of subjects enrolled	Italy: 30
Country: Number of subjects enrolled	Japan: 101
Country: Number of subjects enrolled	Korea, Republic of: 14
Country: Number of subjects enrolled	Lithuania: 3
Country: Number of subjects enrolled	Latvia: 5
Country: Number of subjects enrolled	Malaysia: 7
Country: Number of subjects enrolled	Netherlands: 12
Country: Number of subjects enrolled	Peru: 1

Country: Number of subjects enrolled	Portugal: 8
Country: Number of subjects enrolled	Romania: 5
Country: Number of subjects enrolled	Russian Federation: 9
Country: Number of subjects enrolled	Taiwan: 10
Country: Number of subjects enrolled	Ukraine: 33
Country: Number of subjects enrolled	United States: 59
Worldwide total number of subjects	578
EEA total number of subjects	255

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	321
From 65 to 84 years	256
85 years and over	1

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This study included chemotherapy-naive subjects with histologically or cytologically confirmed Stage IV non-squamous non-small cell lung cancer (NSCLC).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm B (Carboplatin or Cisplatin + Pemetrexed)

Arm description:

Participants received IV infusion of 500 mg/m² pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m² cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m² of pemetrexed on Day 1 q3w until disease progression in the maintenance period.

Arm type	Active comparator
Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin - induction treatment: AUC of 6 mg/mL/min by IV infusion q3w for 4 or 6 cycles

Investigational medicinal product name	Pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pemetrexed - induction treatment: 500 mg/m² q3w by IV infusion for 4 or 6 cycles.

Pemetrexed - maintenance treatment: 500 mg/m² q3w by IV infusion until progressive disease.

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Cisplatin - induction treatment: 75 mg/m² by IV infusion q3w for 4 or 6 cycles

Arm title	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
------------------	--

Arm description:

Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m²) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m² cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m² of pemetrexed on Day 1 q3w until disease progression in the maintenance period.

Arm type	Experimental
Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	Tecentriq
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Atezolizumab - induction treatment: 1200 mg by IV infusion for 4 – 6 cycles of 21 days (q3w). Atezolizumab - maintenance treatment: 1200 mg by IV infusion q3w until progressive disease or loss of clinical benefit.

Investigational medicinal product name	Pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pemetrexed - induction treatment: 500 mg/m² q3w by IV infusion for 4 or 6 cycles.
Pemetrexed - maintenance treatment: 500 mg/m² q3w by IV infusion until progressive disease.

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Cisplatin - induction treatment: 75 mg/m² by IV infusion q3w for 4 or 6 cycles

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin - induction treatment: AUC of 6 mg/mL/min by IV infusion q3w for 4 or 6 cycles

Number of subjects in period 1	Arm B (Carboplatin or Cisplatin + Pemetrexed)	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
	Started	286
Completed	0	0
Not completed	286	292

Consent withdrawn by subject	28	17
Physician decision	-	1
Study terminated by Sponsor	64	82
Death	189	190
Lost to follow-up	2	2
Randomization by error	2	-
Protocol deviation	1	-

Baseline characteristics

Reporting groups

Reporting group title	Arm B (Carboplatin or Cisplatin + Pemetrexed)
-----------------------	---

Reporting group description:

Participants received IV infusion of 500 mg/m² pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m² cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m² of pemetrexed on Day 1 q3w until disease progression in the maintenance period.

Reporting group title	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
-----------------------	--

Reporting group description:

Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m²) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m² cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m² of pemetrexed on Day 1 q3w until disease progression in the maintenance period.

Reporting group values	Arm B (Carboplatin or Cisplatin + Pemetrexed)	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)	Total
Number of subjects	286	292	578
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	168	153	321
From 65-84 years	118	138	256
85 years and over	0	1	1
Age Continuous Units: Years			
arithmetic mean	61.8	63.3	-
standard deviation	± 9.4	± 9.4	-
Sex: Female, Male Units: Participants			
Female	94	100	194
Male	192	192	384
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	1	1	2
Asian	65	71	136
Native Hawaiian or Other Pacific Islander	0	0	0

Black or African American	4	2	6
White	203	193	396
More than one race	0	0	0
Unknown or Not Reported	13	25	38
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	21	17	38
Not Hispanic or Latino	241	243	484
Unknown or Not Reported	24	32	56

End points

End points reporting groups

Reporting group title	Arm B (Carboplatin or Cisplatin + Pemetrexed)
-----------------------	---

Reporting group description:

Participants received IV infusion of 500 mg/m² pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m² cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m² of pemetrexed on Day 1 q3w until disease progression in the maintenance period.

Reporting group title	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
-----------------------	--

Reporting group description:

Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m²) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m² cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m² of pemetrexed on Day 1 q3w until disease progression in the maintenance period.

Primary: Progression Free Survival (PFS) as assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

End point title	Progression Free Survival (PFS) as assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
-----------------	--

End point description:

PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurred first.

End point type	Primary
----------------	---------

End point timeframe:

Randomization up to approximately 39 months

End point values	Arm B (Carboplatin or Cisplatin + Pemetrexed)	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	286	292		
Units: Months				
median (confidence interval 95%)	5.2 (4.3 to 5.6)	7.7 (6.7 to 8.5)		

Statistical analyses

Statistical analysis title	PFS Statistical Analysis
----------------------------	--------------------------

Statistical analysis description:

Unstratified Analysis

Comparison groups	Arm B (Carboplatin or Cisplatin + Pemetrexed) v Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
Number of subjects included in analysis	578
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Logrank
Parameter estimate	Log hazard ratio
Point estimate	0.562
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.471
upper limit	0.671

Primary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description: OS is defined as time from randomization to death from any cause.	
End point type	Primary
End point timeframe: Randomization up to approximately 39 months	

End point values	Arm B (Carboplatin or Cisplatin + Pemetrexed)	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	286	292		
Units: Months				
median (confidence interval 95%)	13.6 (11.0 to 15.7)	17.5 (13.2 to 19.6)		

Statistical analyses

Statistical analysis title	OS Statistical Analysis (Unstratified Analysis)
Comparison groups	Arm B (Carboplatin or Cisplatin + Pemetrexed) v Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)

Number of subjects included in analysis	578
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1559
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.866
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.709
upper limit	1.056

Statistical analysis title	OS Statistical Analysis (Stratified Analysis)
Comparison groups	Arm B (Carboplatin or Cisplatin + Pemetrexed) v Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
Number of subjects included in analysis	578
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1546
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.864
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.707
upper limit	1.056

Secondary: Overall Survival Rate Year 2

End point title	Overall Survival Rate Year 2
End point description: The Overall Survival Rate at the 2-year landmark time point is defined as the probabilities that participants are alive 2-years after randomization.	
End point type	Secondary
End point timeframe: Year 2	

End point values	Arm B (Carboplatin or Cisplatin + Pemetrexed)	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	91	109		
Units: Percentage				
number (confidence interval 95%)	34.01 (28.40 to 39.62)	39.13 (33.44 to 44.81)		

Statistical analyses

Statistical analysis title	OS Rate at 2 Year Statistical Analysis
Comparison groups	Arm B (Carboplatin or Cisplatin + Pemetrexed) v Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
Number of subjects included in analysis	200
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.209
Method	Z-test
Parameter estimate	Difference in Event Free Rate
Point estimate	5.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.87
upper limit	13.11

Secondary: Overall Survival Rate at Year 1

End point title	Overall Survival Rate at Year 1
End point description:	The Overall Survival Rate at the 1-year landmark time point is defined as the probabilities that participants are alive 1-year after randomization.
End point type	Secondary
End point timeframe:	Year 1

End point values	Arm B (Carboplatin or Cisplatin + Pemetrexed)	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	286	292		
Units: Percentage				
number (confidence interval 95%)	55.04 (49.21	59.72 (54.02		

Statistical analyses

Statistical analysis title	OS Rate at 1 Year Statistical Analysis
Comparison groups	Arm B (Carboplatin or Cisplatin + Pemetrexed) v Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
Number of subjects included in analysis	578
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.2606
Method	z test
Parameter estimate	Difference in event free rate
Point estimate	4.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.47
upper limit	12.83

Secondary: Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1

End point title	Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1
End point description:	DOR is defined as the time interval from the date of the first occurrence of a CR or PR (whichever status is recorded first) until the first date that progressive disease or death is documented, whichever occurs first.
End point type	Secondary
End point timeframe:	Randomization up to approximately 25 months

End point values	Arm B (Carboplatin or Cisplatin + Pemetrexed)	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	286	292		
Units: Months				
number (confidence interval 95%)	6.4 (4.4 to 7.6)	9.5 (6.9 to 12.2)		

Statistical analyses

Statistical analysis title	DOR Statistical Analysis
Comparison groups	Arm B (Carboplatin or Cisplatin + Pemetrexed) v Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
Number of subjects included in analysis	578
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0024
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.45
upper limit	0.85

Secondary: Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1

End point title	Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1
End point description:	An objective response is defined as either an unconfirmed CR or a PR, as determined by the investigator using RECIST v1.1. Objective Response Rate is defined as the proportion of patients who had an objective response.
End point type	Secondary
End point timeframe:	Randomization up to approximately 25 months

End point values	Arm B (Carboplatin or Cisplatin + Pemetrexed)	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	286	292		
Units: Percentage of Participants				
number (not applicable)				
Responders	37.4	51.7		
Non-Responders	62.6	48.3		

Statistical analyses

Statistical analysis title	Objective Response Statistical Analysis
Comparison groups	Arm B (Carboplatin or Cisplatin + Pemetrexed) v Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
Number of subjects included in analysis	578
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0005
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rate
Point estimate	14.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.9
upper limit	22.7

Secondary: Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score

End point title	Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score
-----------------	---

End point description:

EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC QLQ-C30 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥ 10 -point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998). Note: 999999=not available. FU=Follow-Up.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)

End point values	Arm B (Carboplatin or Cisplatin + Pemetrexed)	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	232	242		
Units: Units on a scale				
arithmetic mean (standard deviation)				
Dyspnoea: Week 3 (Arm B n=222)(Arm A n=216)	-1.95 (± 23.97)	-1.39 (± 25.17)		
Dyspnoea: Week 6 (Arm B n=189)(Arm A n=198)	-1.23 (± 23.16)	-4.71 (± 26.66)		
Dyspnoea: Week 9 (Arm B n=166)(Arm A n=179)	0.20 (± 26.34)	-6.33 (± 26.62)		
Dyspnoea: Week 12 (Arm B n=147)(Arm A n=177)	-0.91 (± 27.57)	-3.39 (± 29.10)		
Dyspnoea: Week 15 (Arm B n=140)(Arm A n=164)	-1.67 (± 28.92)	-2.44 (± 28.73)		
Dyspnoea: Week 18 (Arm B n=126)(Arm A n=155)	-2.12 (± 24.85)	-3.44 (± 30.43)		
Dyspnoea: Week 21 (Arm B n=100)(Arm A n=150)	-5.67 (± 29.61)	-2.89 (± 31.83)		
Dyspnoea: Week 24 (Arm B n=97)(Arm A n=136)	-2.75 (± 28.74)	-2.45 (± 31.85)		
Dyspnoea: Week 27 (Arm B n=79)(Arm A n=126)	-2.53 (± 31.47)	-1.32 (± 27.13)		
Dyspnoea: Week 30 (Arm B n=80)(Arm A n=123)	-1.25 (± 32.45)	-2.71 (± 28.50)		
Dyspnoea: Week 33 (Arm B n=73)(Arm A n=107)	-1.83 (± 27.15)	-3.74 (± 30.14)		
Dyspnoea: Week 36 (Arm B n=61)(Arm A n=105)	-3.83 (± 30.49)	-6.67 (± 31.49)		
Dyspnoea: Week 39 (Arm B n=60)(Arm A n=95)	-1.67 (± 31.55)	-8.42 (± 29.16)		
Dyspnoea: Week 42 (Arm B n=51)(Arm A n=95)	-3.27 (± 28.48)	-9.12 (± 28.12)		
Dyspnoea: Week 45 (Arm B n=48)(Arm A n=79)	-6.25 (± 32.00)	-2.11 (± 30.82)		
Dyspnoea: Week 48 (Arm B n=39)(Arm A n=81)	-5.13 (± 32.03)	-7.41 (± 26.87)		
Dyspnoea: Week 51 (Arm B n=36)(Arm A n=80)	-14.81 (± 30.28)	-2.92 (± 26.09)		
Dyspnoea: Week 54 (Arm B n=31)(Arm A n=72)	-9.68 (± 35.69)	-2.78 (± 27.26)		
Dyspnoea: Week 57 (Arm B n=26)(Arm A n=71)	-7.69 (± 28.76)	-5.63 (± 28.72)		
Dyspnoea: Week 60 (Arm B n=18)(Arm A n=56)	-11.11 (± 25.57)	0.00 (± 25.43)		
Dyspnoea: Week 63 (Arm B n=13)(Arm A n=39)	-7.69 (± 14.62)	-5.13 (± 23.62)		
Dyspnoea: Week 66 (Arm B n=7)(Arm A n=37)	-9.52 (± 16.27)	-1.80 (± 24.78)		
Dyspnoea: Week 69 (Arm B n=6)(Arm A n=28)	-16.67 (± 18.26)	-3.57 (± 24.58)		
Dyspnoea: Week 72 (Arm B n=8)(Arm A n=22)	-4.17 (± 27.82)	0.00 (± 27.22)		
Dyspnoea: Week 75 (Arm B n=5)(Arm A n=23)	-6.67 (± 14.91)	-5.80 (± 19.21)		
Dyspnoea: Week 78 (Arm B n=2)(Arm A n=14)	0.00 (± 0.00)	-4.76 (± 25.68)		

Dyspnoea: Week 81 (Arm B n=2)(Arm A n=9)	0.00 (± 0.00)	-11.11 (± 23.57)		
Dyspnoea: Week 84 (Arm B n=2)(Arm A n=8)	0.00 (± 0.00)	-4.17 (± 21.36)		
Dyspnoea: Week 87 (Arm B n=1)(Arm A n=4)	0.00 (± 999999)	8.33 (± 16.67)		
Dyspnoea: Week 90 (Arm B n=1)(Arm A n=2)	0.00 (± 999999)	0.00 (± 0.00)		
Dyspnoea: Week 93 (Arm B n=0)(Arm A n=1)	999999 (± 999999)	0.00 (± 999999)		
Dyspnoea: Time of First Pd (Arm B n=0)(Arm A n=0)	999999 (± 999999)	999999 (± 999999)		
Dyspnoea: Time of Last Tx Dose Arm B n=0; Arm A n=0	999999 (± 999999)	999999 (± 999999)		
Dyspnoea: Survival FU Wk 12 Arm B n=29; Arm A n=25	9.20 (± 35.52)	8.00 (± 42.25)		
Dyspnoea: Survival FU Wk 24 Arm B n=19; Arm A n=7	5.26 (± 25.49)	-14.29 (± 17.82)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score

End point title	Change from Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score
-----------------	--

End point description:

The EORTC QLQ-LC13 module incorporates one multiple item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The EORTC QLQ-LC13 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however, a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998). Note: 999999=not available. ToL=Time of Last. ToF=Time of First. Sur=survival.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)

End point values	Arm B (Carboplatin or Cisplatin + Pemetrexed)	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	230	234		
Units: Units on a scale				
arithmetic mean (standard deviation)				
Coughing: Week 3 (Arm B n=213)(Arm A n=205)	-2.50 (± 25.37)	-3.41 (± 26.90)		

Coughing: Week 6 (Arm B n=187)(Arm A n=190)	-3.57 (± 27.20)	-9.82 (± 26.50)		
Coughing: Week 9 (Arm B n=162)(Arm A n=173)	-1.85 (± 24.43)	-8.29 (± 31.37)		
Coughing: Week 12 (Arm B n=145)(Arm A n=168)	-3.91 (± 28.46)	-10.71 (± 31.66)		
Coughing: Week 15 (Arm B n=137)(Arm A n=159)	-6.33 (± 30.39)	-11.53 (± 29.05)		
Coughing: Week 18 (Arm B n=125)(Arm A n=149)	-4.00 (± 26.97)	-11.63 (± 27.92)		
Coughing: Week 21 (Arm B n=100)(Arm A n=146)	-6.00 (± 27.78)	-10.50 (± 30.76)		
Coughing: Week 24 (Arm B n=97)(Arm A n=133)	-4.81 (± 28.05)	-10.03 (± 33.08)		
Coughing: Week 27 (Arm B n=78)(Arm A n=123)	-3.85 (± 26.85)	-11.65 (± 34.40)		
Coughing: Week 30 (Arm B n=80)(Arm A n=120)	0.42 (± 29.76)	-11.39 (± 31.31)		
Coughing: Week 33 (Arm B n=72)(Arm A n=103)	-0.46 (± 26.53)	-11.97 (± 30.91)		
Coughing: Week 36 (Arm B n=60)(Arm A n=103)	-6.11 (± 31.59)	-12.94 (± 30.33)		
Coughing: Week 39 (Arm B n=60)(Arm A n=92)	-5.00 (± 30.58)	-13.41 (± 32.43)		
Coughing: Week 42 (Arm B n=52)(Arm A n=93)	-8.97 (± 27.31)	-14.70 (± 29.68)		
Coughing: Week 45 (Arm B n=48)(Arm A n=77)	-13.19 (± 28.13)	-14.72 (± 27.83)		
Coughing: Week 48 (Arm B n=39)(Arm A n=79)	-7.69 (± 31.96)	-13.92 (± 32.29)		
Coughing: Week 51 (Arm B n=36)(Arm A n=79)	-17.59 (± 25.80)	-10.97 (± 34.48)		
Coughing: Week 54 (Arm B n=31)(Arm A n=70)	-17.20 (± 27.04)	-13.81 (± 33.81)		
Coughing: Week 57 (Arm B n=26)(Arm A n=69)	-11.54 (± 22.98)	-13.53 (± 29.33)		
Coughing: Week 60 (Arm B n=19)(Arm A n=56)	-14.04 (± 27.92)	-10.71 (± 31.21)		
Coughing: Week 63 (Arm B n=13)(Arm A n=39)	-10.26 (± 21.01)	-12.82 (± 27.16)		
Coughing: Week 66 (Arm B n=7)(Arm A n=37)	-9.52 (± 25.20)	-12.61 (± 28.71)		
Coughing: Week 69 (Arm B n=6)(Arm A n=28)	-11.11 (± 27.22)	-11.90 (± 30.38)		
Coughing: Week 72 (Arm B n=8)(Arm A n=22)	-8.33 (± 23.57)	-16.67 (± 30.43)		
Coughing: Week 75 (Arm B n=5)(Arm A n=23)	-13.33 (± 18.26)	-18.84 (± 28.12)		
Coughing: Week 78 (Arm B n=2)(Arm A n=14)	-16.67 (± 23.57)	-23.81 (± 27.51)		
Coughing: Week 81 (Arm B n=2)(Arm A n=9)	-16.67 (± 23.57)	-18.52 (± 33.79)		
Coughing: Week 84 (Arm B n=2)(Arm A n=8)	-33.33 (± 0.00)	-29.17 (± 27.82)		
Coughing: Week 87 (Arm B n=1)(Arm A n=4)	0.00 (± 999999)	-25.00 (± 31.91)		
Coughing: Week 90 (Arm B n=1)(Arm A n=2)	-33.33 (± 999999)	-16.67 (± 23.57)		
Coughing: Week 93 (Arm B n=0)(Arm A n=1)	999999 (± 999999)	0.00 (± 999999)		
Coughing: Time of First Pd Arm B n=61; Arm A n=70	-6.01 (± 30.13)	-10.48 (± 28.68)		

Coughing: ToL Tx Dose Arm B n=199; Arm A n=201	-5.19 (± 28.05)	-8.13 (± 28.78)		
Coughing: Survival FU Wk 12 Arm B n=28, Arm A n=24	3.57 (± 29.17)	-6.94 (± 34.02)		
Coughing: Survival FU Wk 24 Arm B n=19, Arm A n=7	-8.77 (± 24.45)	-14.29 (± 32.53)		
Dyspnoea: Week 3 (Arm B n=213)(Arm A n=205)	0.21 (± 18.69)	-1.41 (± 17.68)		
Dyspnoea: Week 6 (Arm B n=187)(Arm A n=190)	0.12 (± 17.13)	-1.17 (± 18.85)		
Dyspnoea: Week 9 (Arm B n=162)(Arm A n=173)	0.89 (± 20.68)	-3.34 (± 18.65)		
Dyspnoea: Week 12 (Arm B n=145)(Arm A n=168)	1.15 (± 21.82)	-0.46 (± 21.76)		
Dyspnoea: Week 15 (Arm B n=137)(Arm A n=159)	0.00 (± 21.30)	-1.12 (± 20.78)		
Dyspnoea: Week 18 (Arm B n=125)(Arm A n=149)	-1.07 (± 18.90)	-3.88 (± 21.92)		
Dyspnoea: Week 21 (Arm B n=100)(Arm A n=146)	-3.56 (± 22.77)	-1.45 (± 21.85)		
Dyspnoea: Week 24 (Arm B n=97)(Arm A n=133)	-2.29 (± 21.75)	-0.42 (± 23.82)		
Dyspnoea: Week 27 (Arm B n=78)(Arm A n=123)	-0.71 (± 22.32)	-2.08 (± 19.83)		
Dyspnoea: Week 30 (Arm B n=80)(Arm A n=120)	1.25 (± 22.57)	-2.78 (± 20.33)		
Dyspnoea: Week 33 (Arm B n=72)(Arm A n=103)	0.77 (± 21.45)	-3.02 (± 22.82)		
Dyspnoea: Week 36 (Arm B n=60)(Arm A n=103)	-1.11 (± 20.93)	-2.91 (± 23.70)		
Dyspnoea: Week 39 (Arm B n=60)(Arm A n=92)	1.30 (± 26.91)	-4.95 (± 22.31)		
Dyspnoea: Week 42 (Arm B n=52)(Arm A n=93)	-0.43 (± 22.65)	-6.33 (± 18.64)		
Dyspnoea: Week 45 (Arm B n=48)(Arm A n=77)	-2.08 (± 26.60)	-3.61 (± 21.36)		
Dyspnoea: Week 48 (Arm B n=39)(Arm A n=79)	-4.56 (± 24.94)	-5.34 (± 21.49)		
Dyspnoea: Week 51 (Arm B n=36)(Arm A n=79)	-9.88 (± 21.87)	-1.69 (± 18.41)		
Dyspnoea: Week 54 (Arm B n=31)(Arm A n=70)	-6.45 (± 24.47)	-1.90 (± 19.10)		
Dyspnoea: Week 57 (Arm B n=26)(Arm A n=69)	-2.99 (± 23.42)	-4.99 (± 22.99)		
Dyspnoea: Week 60 (Arm B n=19)(Arm A n=56)	-11.11 (± 23.42)	-0.40 (± 22.32)		
Dyspnoea: Week 63 (Arm B n=13)(Arm A n=39)	-6.84 (± 15.41)	-6.55 (± 23.04)		
Dyspnoea: Week 66 (Arm B n=7)(Arm A n=37)	-9.52 (± 16.27)	-4.50 (± 21.98)		
Dyspnoea: Week 69 (Arm B n=6)(Arm A n=28)	-16.67 (± 21.94)	-4.76 (± 23.12)		
Dyspnoea: Week 72 (Arm B n=8)(Arm A n=22)	-5.56 (± 19.70)	-1.52 (± 24.56)		
Dyspnoea: Week 75 (Arm B n=5)(Arm A n=23)	-6.67 (± 14.91)	-6.76 (± 17.64)		
Dyspnoea: Week 78 (Arm B n=2)(Arm A n=14)	0.00 (± 0.00)	-3.17 (± 21.09)		
Dyspnoea: Week 81 (Arm B n=2)(Arm A n=9)	11.11 (± 15.71)	-9.88 (± 22.53)		
Dyspnoea: Week 84 (Arm B n=2)(Arm A n=8)	0.00 (± 0.00)	-6.94 (± 22.17)		

Dyspnoea: Week 87 (Arm B n=1)(Arm A n=4)	0.00 (± 999999)	-2.78 (± 18.98)		
Dyspnoea: Week 90 (Arm B n=1)(Arm A n=2)	0.00 (± 999999)	5.56 (± 23.57)		
Dyspnoea: Week 93 (Arm B n=0)(Arm A n=1)	999999 (± 999999)	22.22 (± 999999)		
Dyspnoea:Time of First PD Arm B n=61,Arm A n=70	2.37 (± 22.05)	-0.16 (± 24.48)		
Dyspnoea:ToL Tx Dose Arm B n=199, Arm A n=201	3.96 (± 22.74)	0.44 (± 21.83)		
Dyspnoea:Survival FU Wk 12 Arm B n=28,Arm A n=24	9.92 (± 25.90)	13.43 (± 33.73)		
Dyspnoea:Survival FU Wk 24 Arm B n=19,Arm A n=7	4.68 (± 17.50)	4.76 (± 23.00)		
Pain In Chest: Week 3 (Arm B n=213)(Arm A n=205)	-1.25 (± 21.19)	0.81 (± 23.67)		
Pain In Chest: Week 6 (Arm B n=187)(Arm A n=190)	0.71 (± 25.15)	-6.32 (± 24.39)		
Pain In Chest: Week 9 (Arm B n=162)(Arm A n=173)	0.82 (± 24.63)	-4.24 (± 25.57)		
Pain In Chest: Week 12 (Arm B n=145)(Arm A n=168)	-2.07 (± 24.60)	-0.60 (± 27.65)		
Pain In Chest: Week 15 (Arm B n=137)(Arm A n=159)	-1.46 (± 24.88)	-3.56 (± 25.60)		
Pain In Chest: Week 18 (Arm B n=125)(Arm A n=149)	-3.47 (± 26.38)	-3.36 (± 26.77)		
Pain In Chest: Week 21 (Arm B n=100)(Arm A n=146)	-3.33 (± 26.17)	-2.74 (± 25.22)		
Pain In Chest: Week 24 (Arm B n=97)(Arm A n=133)	-2.41 (± 26.89)	-4.76 (± 29.05)		
Pain In Chest: Week 27 (Arm B n=78)(Arm A n=123)	-5.13 (± 29.95)	-2.71 (± 22.82)		
Pain In Chest: Week 30 (Arm B n=80)(Arm A n=120)	-4.17 (± 29.71)	-3.06 (± 27.33)		
Pain In Chest: Week 33 (Arm B n=72)(Arm A n=103)	-0.46 (± 29.86)	-3.88 (± 28.12)		
Pain In Chest: Week 36 (Arm B n=60)(Arm A n=103)	-1.67 (± 31.55)	-2.91 (± 27.26)		
Pain In Chest: Week 39 (Arm B n=60)(Arm A n=92)	-3.89 (± 30.12)	-3.99 (± 27.44)		
Pain In Chest: Week 42 (Arm B n=52)(Arm A n=93)	-7.69 (± 29.24)	-7.17 (± 26.40)		
Pain In Chest: Week 45 (Arm B n=48)(Arm A n=77)	-6.25 (± 29.70)	-5.63 (± 25.02)		
Pain In Chest: Week 48 (Arm B n=39)(Arm A n=79)	-7.69 (± 29.08)	-4.64 (± 24.88)		
Pain In Chest: Week 51 (Arm B n=36)(Arm A n=79)	-11.11 (± 28.73)	-5.49 (± 24.13)		
Pain In Chest: Week 54 (Arm B n=31)(Arm A n=70)	-7.53 (± 29.45)	-4.29 (± 25.33)		
Pain In Chest: Week 57 (Arm B n=26)(Arm A n=69)	-1.28 (± 31.95)	-5.80 (± 26.17)		
Pain In Chest: Week 60 (Arm B n=19)(Arm A n=56)	0.00 (± 22.22)	-3.57 (± 27.47)		
Pain In Chest: Week 63 (Arm B n=13)(Arm A n=39)	-5.13 (± 18.49)	-6.84 (± 25.57)		
Pain In Chest: Week 66 (Arm B n=7)(Arm A n=37)	-4.76 (± 23.00)	-4.50 (± 27.40)		
Pain In Chest: Week 69 (Arm B n=6)(Arm A n=28)	-16.67 (± 18.26)	-5.95 (± 31.50)		
Pain In Chest: Week 72 (Arm B n=8)(Arm A n=22)	-8.33 (± 23.57)	-4.55 (± 23.67)		

Pain In Chest: Week 75 (Arm B n=5)(Arm A n=23)	-6.67 (± 14.91)	0.00 (± 20.10)		
Pain In Chest: Week 78 (Arm B n=2)(Arm A n=14)	0.00 (± 0.00)	0.00 (± 26.15)		
Pain In Chest: Week 81 (Arm B n=2)(Arm A n=9)	0.00 (± 47.14)	7.41 (± 14.70)		
Pain In Chest: Week 84 (Arm B n=2)(Arm A n=8)	0.00 (± 0.00)	4.17 (± 21.36)		
Pain In Chest: Week 87 (Arm B n=1)(Arm A n=4)	-33.33 (± 999999)	8.33 (± 16.67)		
Pain In Chest: Week 90 (Arm B n=1)(Arm A n=2)	-33.33 (± 999999)	0.00 (± 0.00)		
Pain In Chest: Week 93 (Arm B n=0)(Arm A n=1)	999999 (± 999999)	0.00 (± 999999)		
Pain In Chest: ToF Pd (Arm B n=61)(Arm A n=70)	6.56 (± 22.62)	-3.81 (± 29.24)		
Pain In Chest: ToL Tx Dose Arm B n=199 Arm A n=201	1.34 (± 25.26)	-0.83 (± 26.96)		
Pain In Chest:Sur FU Wk12 Arm B n=28 Arm A n=24	5.95 (± 36.35)	-2.78 (± 32.48)		
Pain In Chest: Sur FU Wk 24 Arm B n=19 Arm A n=7	1.75 (± 17.48)	-4.76 (± 29.99)		
Pain In Arm/Shoulder:Wk 3 Arm B n=213 Arm A n=205	-4.69 (± 25.26)	-2.60 (± 24.78)		
Pain In Arm/Shoulder: Wk 6 Arm B n=187 Arm A n=190	-4.46 (± 23.14)	-5.44 (± 25.19)		
Pain In Arm/Shoulder: Wk 9 Arm B n=162 Arm A n=173	-2.88 (± 25.85)	-8.09 (± 28.73)		
Pain In Arm/Shoulder: Wk12 Arm B n=145 Arm A n=168	-6.90 (± 23.54)	-4.37 (± 27.19)		
Pain In Arm/Shoulder:Wk 15 Arm B n=137 Arm A n=159	-3.89 (± 23.24)	-7.34 (± 30.15)		
Pain In Arm/Shoulder:Wk18 Arm B n=125 Arm A n=149	-5.07 (± 25.77)	-6.26 (± 29.09)		
Pain In Arm/Shoulder:Wk21 Arm B n=100 Arm A n=146	-6.00 (± 21.91)	-1.83 (± 28.71)		
Pain In Arm/Shoulder:Wk24 Arm B n=97 Arm A n=133	-2.41 (± 28.16)	-5.26 (± 30.11)		
Pain In Arm/Shoulder:Wk27 Arm B n=78 Arm A n=123	-5.56 (± 28.13)	-3.79 (± 26.72)		
Pain In Arm/Shoulder:Wk30 Arm B n=80 Arm A n=120	1.25 (± 27.27)	-3.33 (± 29.12)		
Pain In Arm/Shoulder:Wk33 Arm B n=72 Arm A n=103	-5.56 (± 25.02)	-1.94 (± 27.54)		
Pain In Arm/Shoulder:Wk36 Arm B n=60 Arm A n=103	-1.67 (± 30.33)	-3.24 (± 31.49)		
Pain In Arm/Shoulder:Wk39 (Arm B n=60)(Arm A n=92)	-5.00 (± 30.58)	-3.99 (± 30.80)		
Pain In Arm/Shoulder:Wk42 (Arm B n=52)(Arm A n=93)	0.00 (± 28.77)	-8.60 (± 25.49)		
Pain In Arm/Shoulder:Wk45 (Arm B n=48)(Arm A n=77)	-0.69 (± 27.06)	-6.06 (± 28.47)		
Pain In Arm/Shoulder:Wk48 (Arm B n=39)(Arm A n=79)	-1.71 (± 27.52)	-4.22 (± 29.89)		
Pain In Arm/Shoulder: Wk51 Arm B n=36 Arm A n=79	-2.78 (± 25.67)	-3.38 (± 27.53)		
Pain In Arm/Shoulder:Wk54 Arm B n=31 Arm A n=70	-1.08 (± 21.92)	-6.19 (± 25.56)		
Pain In Arm/Shoulder:Wk57 Arm B n=26 Arm A n=69	-1.28 (± 22.07)	-2.90 (± 26.65)		
Pain In Arm/Shoulder:Wk 60 Arm B n=19 Arm A n=56	-5.26 (± 20.07)	-4.17 (± 27.75)		

Pain In Arm/Shoulder:Wk 63 Arm B n=13 Arm A n=39	-5.13 (± 18.49)	-3.42 (± 27.35)		
Pain In Arm/Shoulder:Wk 66 Arm B n=7 Arm A n=37	4.76 (± 12.60)	-1.80 (± 31.37)		
Pain In Arm/Shoulder:Wk 69 Arm B n=6 Arm A n=28	0.00 (± 0.00)	-7.14 (± 22.87)		
Pain In Arm/Shoulder:Wk 72 Arm B n=8 Arm A n=22	-8.33 (± 15.43)	-7.58 (± 27.08)		
Pain In Arm/Shoulder:Wk 75 Arm B n=5 Arm A n=23	-6.67 (± 14.91)	-8.70 (± 25.06)		
Pain In Arm/Shoulder:Wk78 Arm B n=2 Arm A n=14	0.00 (± 0.00)	-2.38 (± 24.33)		
Pain In Arm/Shoulder:Wk 81 Arm B n=2 Arm A n=9	0.00 (± 0.00)	3.70 (± 11.11)		
Pain In Arm/Shoulder:Wk84 Arm B n=2 Arm A n=8	0.00 (± 0.00)	4.17 (± 21.36)		
Pain In Arm/Shoulder:Wk 87 Arm B n=1 Arm A n=4	0.00 (± 999999)	-16.67 (± 33.33)		
Pain In Arm/Shoulder:Wk 90 Arm B n=1 Arm A n=2	0.00 (± 999999)	0.00 (± 0.00)		
Pain In Arm/Shoulder:Wk 93 Arm B n=0 Arm A n=1	999999 (± 999999)	0.00 (± 999999)		
Pain In Arm/Shoulder: ToF Pd Arm B n=61 Arm A n=70	2.19 (± 28.46)	1.90 (± 25.94)		
Pain In Arm/Shoulder:ToLTxDose ArmBn=199 ArmAn=201	-0.50 (± 27.11)	0.33 (± 30.55)		
Pain In Arm/Shoulder:Sur FU Wk12 ArmBn=28 ArmAn=24	13.10 (± 30.55)	5.56 (± 40.13)		
Pain In Arm/Shoulder:Sur FU Wk24 ArmBn=19 ArmAn=7	1.75 (± 28.27)	0.00 (± 0.00)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score

End point title	Change from Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score
-----------------	--

End point description:

Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms & are scored at individual symptom level, thus have a dyspnea score, chest pain score, & cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 & maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 & 2, 'Cough' score is mean of question 3 & 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥ 0.3 points for dyspnea & cough symptom scores is considered to be clinically significant; whereas a score change of ≥ 0.5 points for chest pain score is considered to be clinically significant. Note: 999999=not available. ToF=Time of First. ToL=Time of Last.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)

End point values	Arm B (Carboplatin or Cisplatin + Pemetrexed)	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	200		
Units: Units on a scale				
arithmetic mean (standard deviation)				
Chest Pain: Week 1 (Arm B n=160)(Arm A n=186)	0.20 (± 0.83)	0.30 (± 0.88)		
Chest Pain: Week 2 (Arm B n=152)(Arm A n=176)	-0.01 (± 0.88)	0.21 (± 0.85)		
Chest Pain: Week 3 (Arm B n=151)(Arm A n=165)	-0.05 (± 0.92)	0.06 (± 0.95)		
Chest Pain: Week 4 (Arm B n=144)(Arm A n=160)	0.03 (± 0.91)	0.03 (± 0.93)		
Chest Pain: Week 5 (Arm B n=143)(Arm A n=166)	-0.02 (± 0.93)	-0.01 (± 0.88)		
Chest Pain: Week 6 (Arm B n=132)(Arm A n=166)	-0.05 (± 0.88)	-0.02 (± 0.92)		
Chest Pain: Week 7 (Arm B n=132)(Arm A n=156)	0.07 (± 1.00)	-0.04 (± 1.00)		
Chest Pain: Week 8 (Arm B n=124)(Arm A n=157)	0.03 (± 0.94)	-0.07 (± 1.02)		
Chest Pain: Week 9 (Arm B n=125)(Arm A n=159)	0.06 (± 1.00)	-0.03 (± 1.03)		
Chest Pain: Week 10 (Arm B n=120)(Arm A n=152)	0.03 (± 1.02)	0.02 (± 1.05)		
Chest Pain: Week 11 (Arm B n=117)(Arm A n=156)	0.02 (± 0.96)	0.04 (± 1.09)		
Chest Pain: Week 12 (Arm B n=116)(Arm A n=142)	-0.02 (± 0.96)	-0.01 (± 1.02)		
Chest Pain: Week 13 (Arm B n=108)(Arm A n=142)	-0.05 (± 1.02)	0.05 (± 0.97)		
Chest Pain: Week 14 (Arm B n=103)(Arm A n=132)	-0.07 (± 1.12)	0.06 (± 1.06)		
Chest Pain: Week 15 (Arm B n=101)(Arm A n=133)	0.13 (± 1.16)	0.08 (± 0.94)		
Chest Pain: Week 16 (Arm B n=100)(Arm A n=133)	0.02 (± 1.08)	0.08 (± 1.04)		
Chest Pain: Week 17 (Arm B n=97)(Arm A n=131)	0.02 (± 1.08)	0.00 (± 1.08)		
Chest Pain: Week 18 (Arm B n=88)(Arm A n=121)	-0.06 (± 1.11)	0.12 (± 1.07)		
Chest Pain: Week 19 (Arm B n=81)(Arm A n=122)	-0.15 (± 1.12)	0.02 (± 1.01)		
Chest Pain: Week 20 (Arm B n=71)(Arm A n=112)	-0.02 (± 1.22)	-0.01 (± 1.03)		
Chest Pain: Week 21 (Arm B n=74)(Arm A n=114)	0.03 (± 1.28)	0.01 (± 1.03)		
Chest Pain: Week 22 (Arm B n=65)(Arm A n=106)	0.04 (± 1.21)	0.02 (± 1.02)		
Chest Pain: Week 23 (Arm B n=65)(Arm A n=106)	-0.08 (± 1.14)	0.04 (± 0.96)		
Chest Pain: Week 24 (Arm B n=64)(Arm A n=106)	-0.02 (± 1.16)	0.09 (± 0.99)		

Chest Pain: Week 25 (Arm B n=60)(Arm A n=100)	0.05 (± 1.24)	0.14 (± 1.03)		
Chest Pain: Week 26 (Arm B n=55)(Arm A n=100)	-0.05 (± 1.14)	0.09 (± 1.00)		
Chest Pain: Week 27 (Arm B n=55)(Arm A n=99)	0.04 (± 1.17)	0.04 (± 1.01)		
Chest Pain: Week 28 (Arm B n=55)(Arm A n=96)	0.24 (± 1.18)	0.03 (± 0.93)		
Chest Pain: Week 29 (Arm B n=54)(Arm A n=99)	0.06 (± 1.29)	0.04 (± 0.95)		
Chest Pain: Week 30 (Arm B n=52)(Arm A n=95)	0.01 (± 1.37)	0.04 (± 0.97)		
Chest Pain: Week 31 (Arm B n=44)(Arm A n=93)	0.02 (± 1.09)	0.05 (± 0.88)		
Chest Pain: Week 32 (Arm B n=39)(Arm A n=94)	0.21 (± 1.21)	-0.01 (± 0.98)		
Chest Pain: Week 33 (Arm B n=41)(Arm A n=85)	0.04 (± 1.17)	0.03 (± 0.92)		
Chest Pain: Week 34 (Arm B n=40)(Arm A n=84)	0.21 (± 1.27)	0.11 (± 0.99)		
Chest Pain: Week 35 (Arm B n=39)(Arm A n=87)	0.33 (± 1.30)	0.11 (± 0.98)		
Chest Pain: Week 36 (Arm B n=34)(Arm A n=86)	0.15 (± 1.07)	0.17 (± 1.04)		
Chest Pain: Week 37 (Arm B n=33)(Arm A n=86)	0.15 (± 1.21)	0.06 (± 0.94)		
Chest Pain: Week 38 (Arm B n=30)(Arm A n=80)	0.12 (± 1.16)	0.04 (± 1.03)		
Chest Pain: Week 39 (Arm B n=32)(Arm A n=72)	0.20 (± 1.23)	0.13 (± 1.01)		
Chest Pain: Week 40 (Arm B n=31)(Arm A n=77)	0.15 (± 1.31)	0.04 (± 0.96)		
Chest Pain: Week 41 (Arm B n=30)(Arm A n=74)	-0.05 (± 1.06)	0.09 (± 1.03)		
Chest Pain: Week 42 (Arm B n=27)(Arm A n=73)	-0.06 (± 1.07)	0.03 (± 1.02)		
Chest Pain: Week 43 (Arm B n=23)(Arm A n=76)	-0.22 (± 0.82)	0.13 (± 1.02)		
Chest Pain: Week 44 (Arm B n=25)(Arm A n=72)	-0.10 (± 1.29)	0.10 (± 1.04)		
Chest Pain: Week 45 (Arm B n=25)(Arm A n=69)	-0.20 (± 1.24)	0.03 (± 0.95)		
Chest Pain: Week 46 (Arm B n=24)(Arm A n=67)	-0.06 (± 1.18)	0.08 (± 0.99)		
Chest Pain: Week 47 (Arm B n=23)(Arm A n=63)	0.02 (± 1.09)	0.09 (± 0.91)		
Chest Pain: Week 48 (Arm B n=25)(Arm A n=64)	0.02 (± 1.27)	0.05 (± 1.00)		
Chest Pain: Week 49 (Arm B n=23)(Arm A n=62)	-0.09 (± 1.07)	0.03 (± 0.90)		
Chest Pain: Week 50 (Arm B n=23)(Arm A n=58)	-0.13 (± 0.99)	0.00 (± 1.03)		
Chest Pain: Week 51 (Arm B n=21)(Arm A n=62)	-0.02 (± 0.77)	0.12 (± 0.94)		
Chest Pain: Week 52 (Arm B n=21)(Arm A n=55)	0.14 (± 1.06)	0.00 (± 1.11)		
Chest Pain: Week 53 (Arm B n=23)(Arm A n=54)	0.13 (± 1.35)	-0.01 (± 1.06)		
Chest Pain: Week 54 (Arm B n=22)(Arm A n=54)	0.11 (± 1.16)	-0.08 (± 1.10)		
Chest Pain: Week 55 (Arm B n=21)(Arm A n=49)	0.12 (± 1.38)	0.03 (± 1.14)		

Chest Pain: Week 56 (Arm B n=20)(Arm A n=53)	0.13 (± 1.46)	0.04 (± 1.18)		
Chest Pain: Week 57 (Arm B n=17)(Arm A n=46)	0.12 (± 1.21)	-0.01 (± 1.15)		
Chest Pain: Week 58 (Arm B n=15)(Arm A n=43)	0.27 (± 0.98)	-0.12 (± 1.10)		
Chest Pain: Week 59 (Arm B n=13)(Arm A n=40)	0.23 (± 0.73)	-0.23 (± 1.01)		
Chest Pain: Week 60 (Arm B n=11)(Arm A n=41)	0.14 (± 0.67)	-0.15 (± 1.17)		
Chest Pain: Week 61 (Arm B n=13)(Arm A n=43)	0.23 (± 0.83)	0.00 (± 1.06)		
Chest Pain: Week 62 (Arm B n=13)(Arm A n=37)	0.46 (± 0.72)	-0.04 (± 1.08)		
Chest Pain: Week 63 (Arm B n=12)(Arm A n=36)	0.25 (± 0.75)	-0.06 (± 1.09)		
Chest Pain: Week 64 (Arm B n=10)(Arm A n=35)	0.15 (± 0.78)	0.09 (± 0.95)		
Chest Pain: Week 65 (Arm B n=9)(Arm A n=33)	0.11 (± 0.82)	-0.03 (± 0.99)		
Chest Pain: Week 66 (Arm B n=6)(Arm A n=34)	0.42 (± 0.92)	0.13 (± 1.05)		
Chest Pain: Week 67 (Arm B n=7)(Arm A n=30)	0.36 (± 0.85)	0.02 (± 1.00)		
Chest Pain: Week 68 (Arm B n=6)(Arm A n=30)	0.33 (± 0.88)	0.12 (± 1.18)		
Chest Pain: Week 69 (Arm B n=7)(Arm A n=29)	0.07 (± 0.93)	-0.05 (± 1.10)		
Chest Pain: Week 70 (Arm B n=6)(Arm A n=30)	0.25 (± 0.88)	0.03 (± 1.11)		
Chest Pain: Week 71 (Arm B n=5)(Arm A n=26)	0.30 (± 0.97)	0.04 (± 1.09)		
Chest Pain: Week 72 (Arm B n=4)(Arm A n=25)	-0.13 (± 0.25)	-0.22 (± 0.94)		
Chest Pain: Week 73 (Arm B n=4)(Arm A n=24)	0.13 (± 1.31)	-0.10 (± 1.01)		
Chest Pain: Week 74 (Arm B n=4)(Arm A n=23)	0.38 (± 1.11)	-0.02 (± 1.14)		
Chest Pain: Week 75 (Arm B n=4)(Arm A n=21)	0.38 (± 1.11)	-0.07 (± 1.14)		
Chest Pain: Week 76 (Arm B n=3)(Arm A n=17)	0.00 (± 0.50)	-0.06 (± 1.20)		
Chest Pain: Week 77 (Arm B n=2)(Arm A n=17)	-0.25 (± 0.35)	-0.21 (± 1.03)		
Chest Pain: Week 78 (Arm B n=2)(Arm A n=14)	-0.75 (± 0.35)	-0.25 (± 1.14)		
Chest Pain: Week 79 (Arm B n=2)(Arm A n=14)	0.00 (± 0.71)	-0.18 (± 1.20)		
Chest Pain: Week 80 (Arm B n=2)(Arm A n=13)	-0.25 (± 0.35)	-0.12 (± 0.96)		
Chest Pain: Week 81 (Arm B n=2)(Arm A n=12)	-0.25 (± 0.35)	-0.25 (± 0.89)		
Chest Pain: Week 82 (Arm B n=2)(Arm A n=9)	-0.75 (± 0.35)	0.00 (± 1.25)		
Chest Pain: Week 83 (Arm B n=2)(Arm A n=4)	-0.25 (± 0.35)	-0.50 (± 1.73)		
Chest Pain: Week 84 (Arm B n=2)(Arm A n=5)	0.00 (± 0.71)	-0.30 (± 1.57)		
Chest Pain: Week 85 (Arm B n=1)(Arm A n=5)	-1.00 (± 999999)	-0.20 (± 1.68)		
Chest Pain: Week 86 (Arm B n=1)(Arm A n=4)	0.00 (± 999999)	-0.50 (± 1.73)		

Chest Pain: Week 87 (Arm B n=1)(Arm A n=3)	-1.00 (± 999999)	0.50 (± 0.87)		
Chest Pain: Week 88 (Arm B n=1)(Arm A n=4)	-1.00 (± 999999)	0.00 (± 0.00)		
Chest Pain: Week 89 (Arm B n=1)(Arm A n=2)	-1.00 (± 999999)	0.00 (± 0.00)		
Chest Pain: Week 90 (Arm B n=1)(Arm A n=2)	0.00 (± 999999)	0.00 (± 0.00)		
Chest Pain: Week 91 (Arm B n=1)(Arm A n=2)	0.00 (± 999999)	0.00 (± 0.00)		
Chest Pain: Week 92 (Arm B n=0)(Arm A n=2)	999999 (± 999999)	0.00 (± 0.00)		
Chest Pain: Week 93 (Arm B n=0)(Arm A n=2)	999999 (± 999999)	0.00 (± 0.00)		
Chest Pain: Week 94 (Arm B n=0)(Arm A n=1)	999999 (± 999999)	1.00 (± 999999)		
Chest Pain: Week 95 (Arm B n=0)(Arm A n=1)	999999 (± 999999)	0.50 (± 999999)		
Chest Pain: ToF Pd (Arm B n=110)(Arm A n=96)	0.28 (± 1.06)	0.20 (± 0.91)		
Chest Pain: ToLTx Dose (Arm B n=141)(Arm A n=150)	0.17 (± 1.17)	0.13 (± 0.98)		
Cough: Week 1 (Arm B n=160)(Arm A n=186)	-0.08 (± 0.74)	-0.06 (± 0.89)		
Cough: Week 2 (Arm B n=152)(Arm A n=176)	-0.13 (± 0.73)	-0.08 (± 0.90)		
Cough: Week 3 (Arm B n=151)(Arm A n=165)	-0.05 (± 0.77)	-0.07 (± 0.81)		
Cough: Week 4 (Arm B n=144)(Arm A n=160)	-0.11 (± 0.89)	-0.22 (± 0.85)		
Cough: Week 5 (Arm B n=143)(Arm A n=166)	-0.14 (± 0.83)	-0.33 (± 0.89)		
Cough: Week 6 (Arm B n=132)(Arm A n=166)	-0.16 (± 0.85)	-0.33 (± 0.91)		
Cough: Week 7 (Arm B n=132)(Arm A n=156)	-0.22 (± 0.89)	-0.22 (± 0.97)		
Cough: Week 8 (Arm B n=124)(Arm A n=157)	-0.20 (± 0.89)	-0.28 (± 0.98)		
Cough: Week 9 (Arm B n=125)(Arm A n=159)	-0.17 (± 0.91)	-0.29 (± 0.97)		
Cough: Week 10 (Arm B n=120)(Arm A n=152)	-0.22 (± 0.95)	-0.35 (± 1.06)		
Cough: Week 11 (Arm B n=117)(Arm A n=156)	-0.21 (± 0.99)	-0.33 (± 1.02)		
Cough: Week 12 (Arm B n=116)(Arm A n=142)	-0.13 (± 1.05)	-0.40 (± 0.96)		
Cough: Week 13 (Arm B n=108)(Arm A n=142)	-0.24 (± 1.05)	-0.37 (± 1.04)		
Cough: Week 14 (Arm B n=103)(Arm A n=132)	-0.23 (± 0.98)	-0.34 (± 1.03)		
Cough: Week 15 (Arm B n=101)(Arm A n=133)	-0.11 (± 1.03)	-0.33 (± 1.03)		
Cough: Week 16 (Arm B n=100)(Arm A n=133)	-0.20 (± 1.05)	-0.33 (± 1.04)		
Cough: Week 17 (Arm B n=97)(Arm A n=131)	-0.20 (± 1.11)	-0.31 (± 0.99)		
Cough: Week 18 (Arm B n=88)(Arm A n=121)	-0.19 (± 1.12)	-0.31 (± 1.00)		
Cough: Week 19 (Arm B n=81)(Arm A n=122)	-0.25 (± 1.07)	-0.36 (± 1.06)		
Cough: Week 20 (Arm B n=71)(Arm A n=112)	-0.25 (± 1.16)	-0.39 (± 0.99)		

Cough: Week 21 (Arm B n=74)(Arm A n=114)	-0.19 (± 1.09)	-0.36 (± 1.07)		
Cough: Week 22 (Arm B n=65)(Arm A n=106)	-0.29 (± 1.11)	-0.41 (± 1.08)		
Cough: Week 23 (Arm B n=65)(Arm A n=106)	-0.34 (± 1.07)	-0.44 (± 1.04)		
Cough: Week 24 (Arm B n=64)(Arm A n=106)	-0.27 (± 0.96)	-0.29 (± 1.13)		
Cough: Week 25 (Arm B n=60)(Arm A n=100)	-0.24 (± 1.11)	-0.27 (± 1.10)		
Cough: Week 26 (Arm B n=55)(Arm A n=100)	-0.25 (± 1.16)	-0.22 (± 1.22)		
Cough: Week 27 (Arm B n=55)(Arm A n=99)	-0.19 (± 0.99)	-0.32 (± 1.11)		
Cough: Week 28 (Arm B n=55)(Arm A n=96)	-0.19 (± 1.04)	-0.32 (± 1.12)		
Cough: Week 29 (Arm B n=54)(Arm A n=99)	-0.25 (± 1.13)	-0.34 (± 1.11)		
Cough: Week 30 (Arm B n=52)(Arm A n=95)	-0.08 (± 1.12)	-0.34 (± 1.00)		
Cough: Week 31 (Arm B n=44)(Arm A n=93)	-0.13 (± 1.13)	-0.37 (± 0.99)		
Cough: Week 32 (Arm B n=39)(Arm A n=94)	0.01 (± 1.09)	-0.45 (± 0.94)		
Cough: Week 33 (Arm B n=41)(Arm A n=85)	0.05 (± 1.17)	-0.44 (± 0.99)		
Cough: Week 34 (Arm B n=40)(Arm A n=84)	-0.10 (± 1.09)	-0.29 (± 1.02)		
Cough: Week 35 (Arm B n=39)(Arm A n=87)	-0.27 (± 1.05)	-0.32 (± 0.99)		
Cough: Week 36 (Arm B n=34)(Arm A n=86)	0.01 (± 1.10)	-0.31 (± 0.99)		
Cough: Week 37 (Arm B n=33)(Arm A n=86)	-0.11 (± 1.16)	-0.37 (± 1.01)		
Cough: Week 38 (Arm B n=30)(Arm A n=80)	0.02 (± 1.03)	-0.31 (± 1.03)		
Cough: Week 39 (Arm B n=32)(Arm A n=72)	0.02 (± 1.19)	-0.33 (± 0.98)		
Cough: Week 40 (Arm B n=31)(Arm A n=77)	-0.10 (± 1.15)	-0.35 (± 1.07)		
Cough: Week 41 (Arm B n=30)(Arm A n=74)	-0.27 (± 1.10)	-0.30 (± 1.09)		
Cough: Week 42 (Arm B n=27)(Arm A n=73)	-0.31 (± 1.04)	-0.31 (± 1.04)		
Cough: Week 43 (Arm B n=23)(Arm A n=76)	-0.20 (± 1.04)	-0.37 (± 0.98)		
Cough: Week 44 (Arm B n=25)(Arm A n=72)	0.00 (± 1.04)	-0.36 (± 1.03)		
Cough: Week 45 (Arm B n=25)(Arm A n=69)	-0.18 (± 1.14)	-0.41 (± 1.04)		
Cough: Week 46 (Arm B n=24)(Arm A n=67)	-0.25 (± 1.04)	-0.34 (± 1.17)		
Cough: Week 47 (Arm B n=23)(Arm A n=63)	-0.43 (± 1.09)	-0.29 (± 1.17)		
Cough: Week 48 (Arm B n=25)(Arm A n=64)	-0.26 (± 1.16)	-0.38 (± 1.08)		
Cough: Week 49 (Arm B n=23)(Arm A n=62)	-0.50 (± 1.07)	-0.40 (± 1.10)		
Cough: Week 50 (Arm B n=23)(Arm A n=58)	-0.37 (± 0.84)	-0.40 (± 1.06)		
Cough: Week 51 (Arm B n=21)(Arm A n=62)	-0.45 (± 1.16)	-0.15 (± 1.10)		

Cough: Week 52 (Arm B n=21)(Arm A n=55)	-0.29 (± 1.07)	-0.10 (± 1.17)		
Cough: Week 53 (Arm B n=23)(Arm A n=54)	-0.24 (± 1.21)	-0.13 (± 1.17)		
Cough: Week 54 (Arm B n=22)(Arm A n=54)	-0.27 (± 1.10)	-0.16 (± 1.15)		
Cough: Week 55 (Arm B n=21)(Arm A n=49)	-0.10 (± 1.15)	-0.35 (± 1.13)		
Cough: Week 56 (Arm B n=20)(Arm A n=53)	-0.30 (± 1.14)	-0.26 (± 1.17)		
Cough: Week 57 (Arm B n=17)(Arm A n=46)	-0.41 (± 0.92)	-0.25 (± 1.10)		
Cough: Week 58 (Arm B n=15)(Arm A n=43)	-0.17 (± 1.05)	-0.45 (± 0.96)		
Cough: Week 59 (Arm B n=13)(Arm A n=40)	-0.31 (± 0.93)	-0.50 (± 1.02)		
Cough: Week 60 (Arm B n=11)(Arm A n=41)	-0.55 (± 1.04)	-0.52 (± 1.03)		
Cough: Week 61 (Arm B n=13)(Arm A n=43)	-0.23 (± 1.15)	-0.38 (± 1.07)		
Cough: Week 62 (Arm B n=13)(Arm A n=37)	0.04 (± 1.03)	-0.53 (± 1.15)		
Cough: Week 63 (Arm B n=12)(Arm A n=36)	-0.29 (± 1.18)	-0.57 (± 1.10)		
Cough: Week 64 (Arm B n=10)(Arm A n=35)	-0.45 (± 1.04)	-0.49 (± 1.01)		
Cough: Week 65 (Arm B n=9)(Arm A n=33)	-0.61 (± 0.96)	-0.39 (± 0.94)		
Cough: Week 66 (Arm B n=6)(Arm A n=34)	-0.17 (± 0.82)	-0.43 (± 1.18)		
Cough: Week 67 (Arm B n=7)(Arm A n=30)	-0.64 (± 1.07)	-0.47 (± 0.84)		
Cough: Week 68 (Arm B n=6)(Arm A n=30)	-0.75 (± 0.88)	-0.35 (± 1.04)		
Cough: Week 69 (Arm B n=7)(Arm A n=29)	-0.57 (± 1.10)	-0.53 (± 0.90)		
Cough: Week 70 (Arm B n=6)(Arm A n=30)	-0.83 (± 0.93)	-0.43 (± 0.98)		
Cough: Week 71 (Arm B n=5)(Arm A n=26)	-0.90 (± 0.89)	-0.56 (± 1.04)		
Cough: Week 72 (Arm B n=4)(Arm A n=25)	-1.25 (± 0.50)	-0.72 (± 1.15)		
Cough: Week 73 (Arm B n=4)(Arm A n=24)	-0.63 (± 1.11)	-0.77 (± 1.00)		
Cough: Week 74 (Arm B n=4)(Arm A n=23)	-0.63 (± 1.11)	-0.54 (± 0.94)		
Cough: Week 75 (Arm B n=4)(Arm A n=21)	-0.63 (± 1.11)	-0.67 (± 1.00)		
Cough: Week 76 (Arm B n=3)(Arm A n=17)	-1.00 (± 1.00)	-0.65 (± 1.22)		
Cough: Week 77 (Arm B n=2)(Arm A n=17)	-0.50 (± 0.71)	-0.82 (± 1.21)		
Cough: Week 78 (Arm B n=2)(Arm A n=14)	-1.00 (± 0.00)	-0.57 (± 1.04)		
Cough: Week 79 (Arm B n=2)(Arm A n=14)	-0.25 (± 0.35)	-0.64 (± 1.23)		
Cough: Week 80 (Arm B n=2)(Arm A n=13)	-0.50 (± 0.71)	-1.04 (± 1.11)		
Cough: Week 81 (Arm B n=2)(Arm A n=12)	-0.50 (± 0.71)	-0.79 (± 1.05)		
Cough: Week 82 (Arm B n=2)(Arm A n=9)	-0.50 (± 0.71)	-0.89 (± 1.27)		

Cough: Week 83 (Arm B n=2)(Arm A n=4)	-1.00 (± 0.00)	0.13 (± 1.03)		
Cough: Week 84 (Arm B n=2)(Arm A n=5)	-0.50 (± 0.71)	-0.20 (± 1.04)		
Cough: Week 85 (Arm B n=1)(Arm A n=5)	0.00 (± 999999)	0.00 (± 0.87)		
Cough: Week 86 (Arm B n=1)(Arm A n=4)	0.00 (± 999999)	-0.38 (± 0.48)		
Cough: Week 87 (Arm B n=1)(Arm A n=3)	0.00 (± 999999)	-0.83 (± 0.58)		
Cough: Week 88 (Arm B n=1)(Arm A n=4)	0.00 (± 999999)	-0.88 (± 0.48)		
Cough: Week 89 (Arm B n=1)(Arm A n=2)	0.00 (± 999999)	0.00 (± 0.71)		
Cough: Week 90 (Arm B n=1)(Arm A n=2)	0.00 (± 999999)	0.25 (± 1.06)		
Cough: Week 91 (Arm B n=1)(Arm A n=2)	0.00 (± 999999)	-0.50 (± 0.00)		
Cough: Week 92 (Arm B n=0)(Arm A n=2)	999999 (± 999999)	0.50 (± 0.71)		
Cough: Week 93 (Arm B n=0)(Arm A n=2)	999999 (± 999999)	0.50 (± 0.71)		
Cough: Week 94 (Arm B n=0)(Arm A n=1)	999999 (± 999999)	0.50 (± 999999)		
Cough: Week 95 (Arm B n=0)(Arm A n=1)	999999 (± 999999)	0.00 (± 999999)		
Cough: ToF Pd (Arm B n=110)(Arm A n=96)	-0.08 (± 1.12)	-0.45 (± 0.93)		
Cough: ToL Tx Dose (Arm B n=141)(Arm A n=150)	-0.15 (± 0.95)	-0.29 (± 0.91)		
Dyspnoea: Week 1 (Arm B n=160)(Arm A n=186)	0.20 (± 0.82)	0.16 (± 0.81)		
Dyspnoea: Week 2 (Arm B n=152)(Arm A n=176)	0.11 (± 0.76)	0.15 (± 0.82)		
Dyspnoea: Week 3 (Arm B n=151)(Arm A n=165)	0.10 (± 0.71)	0.12 (± 0.70)		
Dyspnoea: Week 4 (Arm B n=144)(Arm A n=160)	0.21 (± 0.84)	0.17 (± 0.95)		
Dyspnoea: Week 5 (Arm B n=143)(Arm A n=166)	0.22 (± 0.82)	0.17 (± 0.91)		
Dyspnoea: Week 6 (Arm B n=132)(Arm A n=166)	0.23 (± 0.82)	0.16 (± 0.95)		
Dyspnoea: Week 7 (Arm B n=132)(Arm A n=156)	0.30 (± 0.93)	0.25 (± 0.92)		
Dyspnoea: Week 8 (Arm B n=124)(Arm A n=157)	0.35 (± 0.87)	0.24 (± 0.96)		
Dyspnoea: Week 9 (Arm B n=125)(Arm A n=159)	0.34 (± 0.89)	0.17 (± 0.91)		
Dyspnoea: Week 10 (Arm B n=120)(Arm A n=152)	0.46 (± 0.93)	0.16 (± 0.92)		
Dyspnoea: Week 11 (Arm B n=117)(Arm A n=156)	0.39 (± 1.01)	0.26 (± 0.96)		
Dyspnoea: Week 12 (Arm B n=116)(Arm A n=142)	0.38 (± 0.96)	0.22 (± 0.90)		
Dyspnoea: Week 13 (Arm B n=108)(Arm A n=142)	0.34 (± 0.96)	0.30 (± 1.02)		
Dyspnoea: Week 14 (Arm B n=103)(Arm A n=132)	0.44 (± 0.95)	0.22 (± 0.99)		
Dyspnoea: Week 15 (Arm B n=101)(Arm A n=133)	0.45 (± 0.94)	0.19 (± 0.95)		
Dyspnoea: Week 16 (Arm B n=100)(Arm A n=133)	0.37 (± 1.06)	0.26 (± 1.02)		

Dyspnoea: Week 17 (Arm B n=97)(Arm A n=131)	0.35 (± 1.04)	0.15 (± 1.00)		
Dyspnoea: Week 18 (Arm B n=88)(Arm A n=121)	0.35 (± 0.99)	0.22 (± 0.99)		
Dyspnoea: Week 19 (Arm B n=81)(Arm A n=122)	0.30 (± 1.02)	0.22 (± 0.97)		
Dyspnoea: Week 20 (Arm B n=71)(Arm A n=112)	0.30 (± 1.09)	0.27 (± 1.06)		
Dyspnoea: Week 21 (Arm B n=74)(Arm A n=114)	0.22 (± 1.03)	0.22 (± 1.05)		
Dyspnoea: Week 22 (Arm B n=65)(Arm A n=106)	0.16 (± 1.10)	0.28 (± 1.03)		
Dyspnoea: Week 23 (Arm B n=65)(Arm A n=106)	0.24 (± 1.05)	0.22 (± 1.03)		
Dyspnoea: Week 24 (Arm B n=64)(Arm A n=106)	0.30 (± 0.98)	0.24 (± 0.99)		
Dyspnoea: Week 25 (Arm B n=60)(Arm A n=100)	0.50 (± 1.05)	0.28 (± 0.99)		
Dyspnoea: Week 26 (Arm B n=55)(Arm A n=100)	0.30 (± 1.05)	0.24 (± 1.04)		
Dyspnoea: Week 27 (Arm B n=55)(Arm A n=99)	0.43 (± 1.17)	0.24 (± 1.06)		
Dyspnoea: Week 28 (Arm B n=55)(Arm A n=96)	0.46 (± 1.02)	0.25 (± 0.97)		
Dyspnoea: Week 29 (Arm B n=54)(Arm A n=99)	0.43 (± 1.06)	0.20 (± 1.01)		
Dyspnoea: Week 30 (Arm B n=52)(Arm A n=95)	0.45 (± 1.08)	0.21 (± 0.99)		
Dyspnoea: Week 31 (Arm B n=44)(Arm A n=93)	0.35 (± 1.03)	0.15 (± 0.99)		
Dyspnoea: Week 32 (Arm B n=39)(Arm A n=94)	0.48 (± 1.03)	0.16 (± 1.01)		
Dyspnoea: Week 33 (Arm B n=41)(Arm A n=85)	0.36 (± 0.96)	0.17 (± 0.95)		
Dyspnoea: Week 34 (Arm B n=40)(Arm A n=84)	0.47 (± 1.15)	0.24 (± 1.04)		
Dyspnoea: Week 35 (Arm B n=39)(Arm A n=87)	0.42 (± 1.00)	0.23 (± 1.03)		
Dyspnoea: Week 36 (Arm B n=34)(Arm A n=86)	0.59 (± 1.06)	0.22 (± 1.02)		
Dyspnoea: Week 37 (Arm B n=33)(Arm A n=86)	0.53 (± 1.17)	0.24 (± 1.03)		
Dyspnoea: Week 38 (Arm B n=30)(Arm A n=80)	0.59 (± 1.06)	0.22 (± 1.07)		
Dyspnoea: Week 39 (Arm B n=32)(Arm A n=72)	0.65 (± 1.04)	0.19 (± 1.01)		
Dyspnoea: Week 40 (Arm B n=31)(Arm A n=77)	0.62 (± 1.02)	0.19 (± 0.95)		
Dyspnoea: Week 41 (Arm B n=30)(Arm A n=74)	0.63 (± 1.01)	0.16 (± 0.95)		
Dyspnoea: Week 42 (Arm B n=27)(Arm A n=73)	0.50 (± 1.01)	0.17 (± 0.92)		
Dyspnoea: Week 43 (Arm B n=23)(Arm A n=76)	0.32 (± 0.89)	0.22 (± 0.90)		
Dyspnoea: Week 44 (Arm B n=25)(Arm A n=72)	0.58 (± 0.83)	0.23 (± 0.92)		
Dyspnoea: Week 45 (Arm B n=25)(Arm A n=69)	0.49 (± 0.96)	0.21 (± 0.90)		
Dyspnoea: Week 46 (Arm B n=24)(Arm A n=67)	0.55 (± 1.02)	0.23 (± 0.89)		
Dyspnoea: Week 47 (Arm B n=23)(Arm A n=63)	0.53 (± 1.09)	0.14 (± 0.90)		

Dyspnoea: Week 48 (Arm B n=25)(Arm A n=64)	0.55 (± 0.96)	0.14 (± 0.85)		
Dyspnoea: Week 49 (Arm B n=23)(Arm A n=62)	0.63 (± 1.04)	0.16 (± 0.90)		
Dyspnoea: Week 50 (Arm B n=23)(Arm A n=58)	0.52 (± 0.98)	0.24 (± 0.94)		
Dyspnoea: Week 51 (Arm B n=21)(Arm A n=62)	0.67 (± 1.04)	0.30 (± 0.97)		
Dyspnoea: Week 52 (Arm B n=21)(Arm A n=55)	0.72 (± 1.02)	0.27 (± 1.02)		
Dyspnoea: Week 53 (Arm B n=23)(Arm A n=54)	0.81 (± 1.06)	0.22 (± 0.95)		
Dyspnoea: Week 54 (Arm B n=22)(Arm A n=54)	0.82 (± 1.06)	0.23 (± 0.95)		
Dyspnoea: Week 55 (Arm B n=21)(Arm A n=49)	0.77 (± 1.17)	0.16 (± 0.99)		
Dyspnoea: Week 56 (Arm B n=20)(Arm A n=53)	0.84 (± 1.15)	0.18 (± 0.95)		
Dyspnoea: Week 57 (Arm B n=17)(Arm A n=46)	0.68 (± 1.16)	0.11 (± 0.91)		
Dyspnoea: Week 58 (Arm B n=15)(Arm A n=43)	0.77 (± 1.06)	0.16 (± 0.86)		
Dyspnoea: Week 59 (Arm B n=13)(Arm A n=40)	0.66 (± 0.90)	0.07 (± 0.85)		
Dyspnoea: Week 60 (Arm B n=11)(Arm A n=41)	0.73 (± 0.96)	0.27 (± 0.94)		
Dyspnoea: Week 61 (Arm B n=13)(Arm A n=43)	0.85 (± 1.04)	0.23 (± 0.90)		
Dyspnoea: Week 62 (Arm B n=13)(Arm A n=37)	0.95 (± 1.05)	0.16 (± 0.92)		
Dyspnoea: Week 63 (Arm B n=12)(Arm A n=36)	0.67 (± 1.01)	0.27 (± 0.95)		
Dyspnoea: Week 64 (Arm B n=10)(Arm A n=35)	0.46 (± 0.78)	0.14 (± 0.93)		
Dyspnoea: Week 65 (Arm B n=9)(Arm A n=33)	0.40 (± 0.66)	0.12 (± 0.95)		
Dyspnoea: Week 66 (Arm B n=6)(Arm A n=34)	0.67 (± 0.74)	0.16 (± 0.94)		
Dyspnoea: Week 67 (Arm B n=7)(Arm A n=30)	0.37 (± 0.76)	0.26 (± 1.01)		
Dyspnoea: Week 68 (Arm B n=6)(Arm A n=30)	0.47 (± 0.80)	0.25 (± 1.03)		
Dyspnoea: Week 69 (Arm B n=7)(Arm A n=29)	0.43 (± 0.80)	0.16 (± 1.11)		
Dyspnoea: Week 70 (Arm B n=6)(Arm A n=30)	0.33 (± 0.83)	0.07 (± 0.89)		
Dyspnoea: Week 71 (Arm B n=5)(Arm A n=26)	0.40 (± 0.91)	0.13 (± 0.89)		
Dyspnoea: Week 72 (Arm B n=4)(Arm A n=25)	-0.05 (± 0.25)	0.06 (± 0.91)		
Dyspnoea: Week 73 (Arm B n=4)(Arm A n=24)	0.45 (± 1.04)	0.09 (± 0.99)		
Dyspnoea: Week 74 (Arm B n=4)(Arm A n=23)	0.50 (± 1.01)	0.27 (± 1.19)		
Dyspnoea: Week 75 (Arm B n=4)(Arm A n=21)	0.55 (± 0.97)	0.45 (± 1.31)		
Dyspnoea: Week 76 (Arm B n=3)(Arm A n=17)	-0.07 (± 0.12)	0.02 (± 1.10)		
Dyspnoea: Week 77 (Arm B n=2)(Arm A n=17)	0.00 (± 0.00)	0.09 (± 1.17)		
Dyspnoea: Week 78 (Arm B n=2)(Arm A n=14)	0.00 (± 0.00)	0.03 (± 1.19)		

Dyspnoea: Week 79 (Arm B n=2)(Arm A n=14)	0.00 (± 0.00)	0.19 (± 1.18)		
Dyspnoea: Week 80 (Arm B n=2)(Arm A n=13)	0.10 (± 0.14)	-0.26 (± 0.80)		
Dyspnoea: Week 81 (Arm B n=2)(Arm A n=12)	0.10 (± 0.14)	-0.17 (± 1.15)		
Dyspnoea: Week 82 (Arm B n=2)(Arm A n=9)	0.00 (± 0.00)	0.18 (± 1.54)		
Dyspnoea: Week 83 (Arm B n=2)(Arm A n=4)	0.00 (± 0.00)	0.45 (± 1.22)		
Dyspnoea: Week 84 (Arm B n=2)(Arm A n=5)	0.00 (± 0.00)	0.60 (± 1.10)		
Dyspnoea: Week 85 (Arm B n=1)(Arm A n=5)	0.20 (± 999999)	0.32 (± 1.53)		
Dyspnoea: Week 86 (Arm B n=1)(Arm A n=4)	0.00 (± 999999)	-0.15 (± 0.34)		
Dyspnoea: Week 87 (Arm B n=1)(Arm A n=3)	0.20 (± 999999)	-0.47 (± 0.23)		
Dyspnoea: Week 88 (Arm B n=1)(Arm A n=4)	0.20 (± 999999)	-0.70 (± 0.20)		
Dyspnoea: Week 89 (Arm B n=1)(Arm A n=2)	0.20 (± 999999)	-0.20 (± 0.57)		
Dyspnoea: Week 90 (Arm B n=1)(Arm A n=2)	0.20 (± 999999)	-0.50 (± 0.14)		
Dyspnoea: Week 91 (Arm B n=1)(Arm A n=2)	0.00 (± 999999)	-0.50 (± 0.14)		
Dyspnoea: Week 92 (Arm B n=0)(Arm A n=2)	999999 (± 999999)	-0.70 (± 0.14)		
Dyspnoea: Week 93 (Arm B n=0)(Arm A n=2)	999999 (± 999999)	-0.40 (± 0.28)		
Dyspnoea: Week 94 (Arm B n=0)(Arm A n=1)	999999 (± 999999)	-0.80 (± 999999)		
Dyspnoea: Week 95 (Arm B n=0)(Arm A n=1)	999999 (± 999999)	-1.00 (± 999999)		
Dyspnoea: ToF Pd (Arm B n=110)(Arm A n=96)	0.58 (± 0.99)	0.40 (± 1.06)		
Dyspnoea: ToL Tx Dose (Arm B n=141)(Arm A n=150)	0.47 (± 0.95)	0.18 (± 0.94)		

Statistical analyses

No statistical analyses for this end point

Secondary: Minimum Observed Serum Atezolizumab Concentration (Cmin)

End point title	Minimum Observed Serum Atezolizumab Concentration
-----------------	---

End point description:

Minimum observed serum atezolizumab concentration (Cmin) prior to infusion at selected cycles (Arm A).

End point type	Secondary
----------------	-----------

End point timeframe:

Predose (Prd; 0 hour [h]) on D1 of Cy 2,3,4,8,16 (Cy length=21 days) and thereafter on D1 of every 8th cycle (up to approximately 25 months)

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analysis for this endpoint.

End point values	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)			
Subject group type	Reporting group			
Number of subjects analysed	247			
Units: µg/mL				
arithmetic mean (standard deviation)				
Cy2D1 (n=247)	69.8 (± 32.3)			
Cy3D1 (n=228)	115 (± 51.5)			
Cy4D1 (n=213)	151 (± 69.9)			
Cy8D1 (n=145)	221 (± 101)			
Cy16D1 (n=76)	234 (± 86.7)			
Cy24D1 (n=13)	257 (± 95.1)			
Treatment Discontinuation Visit (n=131)	129 (± 93.1)			
Day 120 Post Last Dose (n=55)	13.4 (± 19.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Serum Atezolizumab Concentration (Cmax)

End point title	Maximum Observed Serum Atezolizumab Concentration
End point description:	Maximum observed serum atezolizumab concentration (Cmax) after infusion (Arm A)
End point type	Secondary
End point timeframe:	Day 1 of Cycle 1 (Cycle length=21 days)

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis for this endpoint.

End point values	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)			
Subject group type	Reporting group			
Number of subjects analysed	273			
Units: µg/mL				
arithmetic mean (standard deviation)				
Cy1D1	403 (± 118)			

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)

End point title	Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) ^[3]
-----------------	---

End point description:

Note: 999999 = not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Prd (0 h), 5-10 minutes (mins) before end of carboplatin infusion (infusion duration=1-2 h), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analysis for this endpoint.

End point values	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: ng/mL				
arithmetic mean (standard deviation)				
Cy1D1 Predose	999999 (± 999999)			
Cy1D1 Before End of Infusion	14900 (± 4260)			
Cy1D1 Post Infusion	12800 (± 4470)			
Cy3D1 Predose	220 (± 83.8)			
Cy3D1 Before End of Infusion	17900 (± 4390)			
Cy3D1 Post Infusion	13900 (± 4080)			

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)

End point title	Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) ^[4]
-----------------	--

End point description:

Note: 999999=not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Prd (0 h), 5-10 mins before end of cisplatin infusion (infusion duration=30-60 mins), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analysis for this endpoint.

End point values	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: ng/mL				
arithmetic mean (standard deviation)				
Cy1D1 Predose	999999 (± 999999)			
Cy1D1 Before End of Infusion	3630 (± 589)			
Cy1D1 Post Infusion	2400 (± 360)			
Cy3D1 Predose	290 (± 86.1)			
Cy3D1 Before End of Infusion	3020 (± 968)			
Cy3D1 Post Infusion	2740 (± 543)			

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)

End point title	Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) ^[5]
End point description:	
Note: 999999=not available.	
End point type	Secondary
End point timeframe:	
	Prd (0 h), 5-10 mins before end of pemetrexed infusion (infusion duration=10 mins), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days)

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analysis for this endpoint.

End point values	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)			
Subject group type	Reporting group			
Number of subjects analysed	36			
Units: ng/mL				
arithmetic mean (standard deviation)				
Cy1D1 Predose	999999 (± 999999)			
Cy1D1 Before End of Infusion	86500 (± 41600)			
Cy1D1 Post Infusion	43600 (± 15800)			
Cy3D1 Predose	1.83 (± 0.681)			
Cy3D1 Before End of Infusion	79400 (± 44400)			

Cy3D1 Post Infusion	50100 (± 26100)			
---------------------	-----------------	--	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) of Atezolizumab

End point title	Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) of Atezolizumab ^[6]
-----------------	---

End point description:

Baseline prevalence and post-baseline incidence of anti-drug antibodies (ADA) to Atezolizumab in the Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)

End point type	Secondary
----------------	-----------

End point timeframe:

Prd (0 h) on D1 of Cy1,2,3,4,8,16 (Cy length=21 days) and thereafter on D1 of every 8th cycle, at treatment discontinuation & then every 30 days (up to 120 days) after last dose of atezolizumab (up to app 25 months)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analysis for this endpoint.

End point values	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)			
Subject group type	Reporting group			
Number of subjects analysed	291			
Units: Percentage of Participants				
number (not applicable)				
Baseline Evaluable Participants	1.8			
Post-Baseline Evaluable Participants	35.4			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the first study drug to the data cutoff date: 13 December 2022 (up to approximately 80 months).

Adverse event reporting additional description:

Adverse events reported based on safety population, which included participants who received any amount of any component of study treatment.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.1
--------------------	------

Reporting groups

Reporting group title	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
-----------------------	--

Reporting group description:

Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m²) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m² cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m² of pemetrexed on Day 1 q3w until disease progression in the maintenance period.

Reporting group title	Arm B (Carboplatin or Cisplatin + Pemetrexed)
-----------------------	---

Reporting group description:

Participants received IV infusion of 500 mg/m² pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m² cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who do not experience disease progression during the induction phase will begin maintenance therapy. Participants will receive IV infusion of 500 mg/m² of pemetrexed on Day 1 q3w until disease progression in the maintenance period.

	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)	Arm B (Carboplatin or Cisplatin + Pemetrexed)	
Serious adverse events			
Total subjects affected by serious adverse events			
subjects affected / exposed	149 / 291 (51.20%)	91 / 274 (33.21%)	
number of deaths (all causes)	199	199	
number of deaths resulting from adverse events	11	8	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
TUMOUR EMBOLISM			
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
ADENOCARCINOMA GASTRIC			

subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CANCER PAIN			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HISTIOCYTIC NECROTISING LYMPHADENITIS			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
METASTASES TO CENTRAL NERVOUS SYSTEM			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PROSTATE CANCER RECURRENT			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
AORTIC EMBOLUS			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
DEEP VEIN THROMBOSIS			
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
EMBOLISM			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTENSION			

subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOTENSION			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL ARTERY THROMBOSIS			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL ISCHAEMIA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
THROMBOPHLEBITIS			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VASCULITIS			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
FATIGUE			
subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEATH			
subjects affected / exposed	2 / 291 (0.69%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	1 / 2	1 / 1	
deaths causally related to treatment / all	1 / 2	1 / 1	
CHEST PAIN			

subjects affected / exposed	0 / 291 (0.00%)	2 / 274 (0.73%)
occurrences causally related to treatment / all	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
ASTHENIA		
subjects affected / exposed	5 / 291 (1.72%)	2 / 274 (0.73%)
occurrences causally related to treatment / all	3 / 5	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
GAIT DISTURBANCE		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
GENERAL PHYSICAL HEALTH DETERIORATION		
subjects affected / exposed	3 / 291 (1.03%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	2 / 4	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
INFLAMMATION		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
MALAISE		
subjects affected / exposed	1 / 291 (0.34%)	2 / 274 (0.73%)
occurrences causally related to treatment / all	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
MUCOSAL INFLAMMATION		
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
NON-CARDIAC CHEST PAIN		
subjects affected / exposed	0 / 291 (0.00%)	2 / 274 (0.73%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
PAIN		

subjects affected / exposed	0 / 291 (0.00%)	2 / 274 (0.73%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PYREXIA			
subjects affected / exposed	12 / 291 (4.12%)	2 / 274 (0.73%)	
occurrences causally related to treatment / all	6 / 12	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
DISEASE SUSCEPTIBILITY			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
HYPERSENSITIVITY			
subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CYTOKINE RELEASE SYNDROME			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
BENIGN PROSTATIC HYPERPLASIA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
PLEURAL EFFUSION			
subjects affected / exposed	1 / 291 (0.34%)	3 / 274 (1.09%)	
occurrences causally related to treatment / all	1 / 1	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATELECTASIS			

subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
BRONCHIAL HYPERREACTIVITY		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
CHRONIC OBSTRUCTIVE PULMONARY DISEASE		
subjects affected / exposed	2 / 291 (0.69%)	2 / 274 (0.73%)
occurrences causally related to treatment / all	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
DYSPNOEA		
subjects affected / exposed	2 / 291 (0.69%)	3 / 274 (1.09%)
occurrences causally related to treatment / all	0 / 4	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
EPISTAXIS		
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
HAEMOPTYSIS		
subjects affected / exposed	2 / 291 (0.69%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0
HYPERVENTILATION		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
INTERSTITIAL LUNG DISEASE		
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	1 / 1	1 / 1
deaths causally related to treatment / all	1 / 1	0 / 0
ORGANISING PNEUMONIA		

subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PHARYNGEAL INFLAMMATION			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMOTHORAX			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY EMBOLISM			
subjects affected / exposed	4 / 291 (1.37%)	4 / 274 (1.46%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 2	0 / 0	
PULMONARY HAEMORRHAGE			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
RESPIRATORY FAILURE			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
PNEUMONITIS			
subjects affected / exposed	9 / 291 (3.09%)	4 / 274 (1.46%)	
occurrences causally related to treatment / all	9 / 9	4 / 4	
deaths causally related to treatment / all	1 / 1	1 / 1	
Psychiatric disorders			
ANXIETY			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CATATONIA			

subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COMPLETED SUICIDE			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Product issues			
DEVICE MALFUNCTION			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	3 / 291 (1.03%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	2 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BLOOD CREATININE INCREASED			
subjects affected / exposed	3 / 291 (1.03%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CREATININE RENAL CLEARANCE DECREASED			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NEUTROPHIL COUNT DECREASED			

subjects affected / exposed	0 / 291 (0.00%)	3 / 274 (1.09%)	
occurrences causally related to treatment / all	0 / 0	5 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
PLATELET COUNT DECREASED			
subjects affected / exposed	1 / 291 (0.34%)	3 / 274 (1.09%)	
occurrences causally related to treatment / all	1 / 1	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
WEIGHT DECREASED			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
WHITE BLOOD CELL COUNT DECREASED			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
INFUSION RELATED REACTION			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEMUR FRACTURE			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTENTIONAL OVERDOSE			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUMBAR VERTEBRAL FRACTURE			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SKIN INJURY			

subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
STAB WOUND			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUBDURAL HAEMATOMA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
TOXICITY TO VARIOUS AGENTS			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FALL			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
TACHYCARDIA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUPRAVENTRICULAR TACHYCARDIA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
STRESS CARDIOMYOPATHY			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MYOCARDITIS			

subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC FAILURE ACUTE			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
CARDIAC FAILURE			
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
ATRIAL FIBRILLATION			
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ACUTE MYOCARDIAL INFARCTION			
subjects affected / exposed	1 / 291 (0.34%)	2 / 274 (0.73%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 1	0 / 1	
Nervous system disorders			
APHASIA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRAIN OEDEMA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CAROTID ARTERY OCCLUSION			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CAROTID ARTERY STENOSIS			

subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
CEREBRAL HAEMORRHAGE		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
CEREBRAL INFARCTION		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
CEREBROVASCULAR ACCIDENT		
subjects affected / exposed	4 / 291 (1.37%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	0 / 4	1 / 1
deaths causally related to treatment / all	0 / 1	1 / 1
HEADACHE		
subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
LETHARGY		
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
SEIZURE		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0
SYNCOPE		
subjects affected / exposed	0 / 291 (0.00%)	2 / 274 (0.73%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
TRANSIENT ISCHAEMIC ATTACK		

subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATAXIA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHANGE IN SEIZURE PRESENTATION			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
FEBRILE BONE MARROW APLASIA			
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEBRILE NEUTROPENIA			
subjects affected / exposed	12 / 291 (4.12%)	5 / 274 (1.82%)	
occurrences causally related to treatment / all	12 / 12	3 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
THROMBOCYTOPENIA			
subjects affected / exposed	11 / 291 (3.78%)	4 / 274 (1.46%)	
occurrences causally related to treatment / all	14 / 15	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
PANCYTOPENIA			
subjects affected / exposed	4 / 291 (1.37%)	4 / 274 (1.46%)	
occurrences causally related to treatment / all	4 / 4	6 / 6	
deaths causally related to treatment / all	0 / 0	1 / 1	
NEUTROPENIA			
subjects affected / exposed	3 / 291 (1.03%)	3 / 274 (1.09%)	
occurrences causally related to treatment / all	3 / 3	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
LEUKOPENIA			

subjects affected / exposed	2 / 291 (0.69%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ANAEMIA			
subjects affected / exposed	11 / 291 (3.78%)	7 / 274 (2.55%)	
occurrences causally related to treatment / all	13 / 14	9 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
MYELOSUPPRESSION			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
CATARACT			
subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
PANCREATITIS			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PROCTITIS ULCERATIVE			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
OESOPHAGITIS			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	3 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
NAUSEA			
subjects affected / exposed	2 / 291 (0.69%)	2 / 274 (0.73%)	
occurrences causally related to treatment / all	1 / 2	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTESTINAL OBSTRUCTION			

subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
INGUINAL HERNIA		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
GASTROINTESTINAL DISORDER		
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
GASTRIC PERFORATION		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
ENTEROCOLITIS		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
DIVERTICULUM INTESTINAL HAEMORRHAGIC		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
DIARRHOEA		
subjects affected / exposed	9 / 291 (3.09%)	3 / 274 (1.09%)
occurrences causally related to treatment / all	8 / 9	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
CONSTIPATION		
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
COLITIS		

subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
AUTOIMMUNE COLITIS			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABDOMINAL PAIN			
subjects affected / exposed	4 / 291 (1.37%)	2 / 274 (0.73%)	
occurrences causally related to treatment / all	3 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
SMALL INTESTINAL PERFORATION			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
VOMITING			
subjects affected / exposed	6 / 291 (2.06%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	4 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
UPPER GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
STOMATITIS			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
CHOLANGITIS			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
AUTOIMMUNE HEPATITIS			

subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEPATOTOXICITY			
subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
HEPATITIS ACUTE			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEPATITIS			
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DRUG-INDUCED LIVER INJURY			
subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLELITHIASIS			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BILIARY OBSTRUCTION			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
CONGESTIVE HEPATOPATHY			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
DERMATITIS			

subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RASH			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RASH MACULO-PAPULAR			
subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	3 / 291 (1.03%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	2 / 3	1 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
CHRONIC KIDNEY DISEASE			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
NEPHRITIS ALLERGIC			
subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL FAILURE			
subjects affected / exposed	1 / 291 (0.34%)	2 / 274 (0.73%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
RENAL IMPAIRMENT			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TUBULOINTERSTITIAL NEPHRITIS			

subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GLYCOSURIA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
HYPOTHYROIDISM			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
BACK PAIN			
subjects affected / exposed	0 / 291 (0.00%)	2 / 274 (0.73%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
BONE PAIN			
subjects affected / exposed	0 / 291 (0.00%)	2 / 274 (0.73%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
FRACTURE PAIN			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MYALGIA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

NECK PAIN			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
BACTERAEMIA			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHITIS			
subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFECTIOUS PLEURAL EFFUSION			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
H3N2 INFLUENZA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
ESCHERICHIA URINARY TRACT INFECTION			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ERYSIPELAS			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENCEPHALITIS			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

DIVERTICULITIS			
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CELLULITIS			
subjects affected / exposed	3 / 291 (1.03%)	2 / 274 (0.73%)	
occurrences causally related to treatment / all	2 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
CAMPYLOBACTER GASTROENTERITIS			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHOPULMONARY ASPERGILLOSIS			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFLUENZA			
subjects affected / exposed	3 / 291 (1.03%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MENINGITIS			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
NEUTROPENIC SEPSIS			
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
OESOPHAGEAL CANDIDIASIS			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL NERVE INFECTION			

subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
PHARYNGITIS		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
PNEUMONIA		
subjects affected / exposed	17 / 291 (5.84%)	16 / 274 (5.84%)
occurrences causally related to treatment / all	6 / 18	5 / 17
deaths causally related to treatment / all	1 / 2	3 / 4
UROSEPSIS		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
URINARY TRACT INFECTION		
subjects affected / exposed	6 / 291 (2.06%)	2 / 274 (0.73%)
occurrences causally related to treatment / all	2 / 6	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
TRACHEITIS		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
SOFT TISSUE INFECTION		
subjects affected / exposed	1 / 291 (0.34%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
SEPSIS		
subjects affected / exposed	4 / 291 (1.37%)	2 / 274 (0.73%)
occurrences causally related to treatment / all	2 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1
RESPIRATORY TRACT INFECTION		

subjects affected / exposed	6 / 291 (2.06%)	2 / 274 (0.73%)
occurrences causally related to treatment / all	1 / 9	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0
PYELONEPHRITIS		
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
PULMONARY SEPSIS		
subjects affected / exposed	2 / 291 (0.69%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
LOWER RESPIRATORY TRACT INFECTION		
subjects affected / exposed	0 / 291 (0.00%)	2 / 274 (0.73%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
PNEUMONIA ASPIRATION		
subjects affected / exposed	2 / 291 (0.69%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
GASTROENTERITIS CLOSTRIDIAL		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
LARYNGOPHARYNGITIS		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
VASCULAR ACCESS SITE CELLULITIS		
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
GASTROENTERITIS		

subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	1 / 291 (0.34%)	2 / 274 (0.73%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	1 / 1	0 / 0	
DEHYDRATION			
subjects affected / exposed	2 / 291 (0.69%)	4 / 274 (1.46%)	
occurrences causally related to treatment / all	2 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIABETES MELLITUS INADEQUATE CONTROL			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GOUT			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERCALCAEMIA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERKALAEMIA			
subjects affected / exposed	0 / 291 (0.00%)	1 / 274 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOKALAEMIA			
subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOMAGNESAEMIA			

subjects affected / exposed	1 / 291 (0.34%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
HYPONATRAEMIA		
subjects affected / exposed	2 / 291 (0.69%)	1 / 274 (0.36%)
occurrences causally related to treatment / all	2 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
HYPERGLYCAEMIA		
subjects affected / exposed	3 / 291 (1.03%)	0 / 274 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)	Arm B (Carboplatin or Cisplatin + Pemetrexed)
Total subjects affected by non-serious adverse events		
subjects affected / exposed	275 / 291 (94.50%)	255 / 274 (93.07%)
Vascular disorders		
HYPERTENSION		
subjects affected / exposed	17 / 291 (5.84%)	7 / 274 (2.55%)
occurrences (all)	31	9
General disorders and administration site conditions		
PYREXIA		
subjects affected / exposed	59 / 291 (20.27%)	37 / 274 (13.50%)
occurrences (all)	89	50
ASTHENIA		
subjects affected / exposed	79 / 291 (27.15%)	54 / 274 (19.71%)
occurrences (all)	118	81
CHEST PAIN		
subjects affected / exposed	22 / 291 (7.56%)	18 / 274 (6.57%)
occurrences (all)	25	18
FATIGUE		

subjects affected / exposed occurrences (all)	71 / 291 (24.40%) 116	68 / 274 (24.82%) 98	
MALAISE subjects affected / exposed occurrences (all)	14 / 291 (4.81%) 23	17 / 274 (6.20%) 23	
MUCOSAL INFLAMMATION subjects affected / exposed occurrences (all)	23 / 291 (7.90%) 24	19 / 274 (6.93%) 28	
OEDEMA PERIPHERAL subjects affected / exposed occurrences (all)	46 / 291 (15.81%) 66	33 / 274 (12.04%) 38	
Respiratory, thoracic and mediastinal disorders			
HICCUPS subjects affected / exposed occurrences (all)	16 / 291 (5.50%) 35	17 / 274 (6.20%) 24	
COUGH subjects affected / exposed occurrences (all)	43 / 291 (14.78%) 58	30 / 274 (10.95%) 36	
DYSPNOEA subjects affected / exposed occurrences (all)	44 / 291 (15.12%) 50	40 / 274 (14.60%) 42	
EPISTAXIS subjects affected / exposed occurrences (all)	13 / 291 (4.47%) 16	19 / 274 (6.93%) 22	
Psychiatric disorders			
INSOMNIA subjects affected / exposed occurrences (all)	28 / 291 (9.62%) 35	18 / 274 (6.57%) 18	
Investigations			
BLOOD CREATININE INCREASED subjects affected / exposed occurrences (all)	34 / 291 (11.68%) 43	20 / 274 (7.30%) 26	
ASPARTATE AMINOTRANSFERASE INCREASED subjects affected / exposed occurrences (all)	51 / 291 (17.53%) 78	27 / 274 (9.85%) 35	
ALANINE AMINOTRANSFERASE			

INCREASED			
subjects affected / exposed	52 / 291 (17.87%)	23 / 274 (8.39%)	
occurrences (all)	74	29	
NEUTROPHIL COUNT DECREASED			
subjects affected / exposed	45 / 291 (15.46%)	48 / 274 (17.52%)	
occurrences (all)	116	108	
PLATELET COUNT DECREASED			
subjects affected / exposed	38 / 291 (13.06%)	38 / 274 (13.87%)	
occurrences (all)	63	69	
WEIGHT DECREASED			
subjects affected / exposed	26 / 291 (8.93%)	16 / 274 (5.84%)	
occurrences (all)	26	17	
WHITE BLOOD CELL COUNT DECREASED			
subjects affected / exposed	20 / 291 (6.87%)	29 / 274 (10.58%)	
occurrences (all)	58	67	
Nervous system disorders			
DIZZINESS			
subjects affected / exposed	19 / 291 (6.53%)	24 / 274 (8.76%)	
occurrences (all)	23	27	
DYSGEUSIA			
subjects affected / exposed	28 / 291 (9.62%)	19 / 274 (6.93%)	
occurrences (all)	33	19	
HEADACHE			
subjects affected / exposed	35 / 291 (12.03%)	24 / 274 (8.76%)	
occurrences (all)	39	26	
PARAESTHESIA			
subjects affected / exposed	12 / 291 (4.12%)	14 / 274 (5.11%)	
occurrences (all)	13	16	
Blood and lymphatic system disorders			
THROMBOCYTOPENIA			
subjects affected / exposed	39 / 291 (13.40%)	23 / 274 (8.39%)	
occurrences (all)	60	37	
NEUTROPENIA			
subjects affected / exposed	48 / 291 (16.49%)	38 / 274 (13.87%)	
occurrences (all)	95	65	
ANAEMIA			

subjects affected / exposed occurrences (all)	129 / 291 (44.33%) 186	113 / 274 (41.24%) 142	
Eye disorders LACRIMATION INCREASED subjects affected / exposed occurrences (all)	16 / 291 (5.50%) 16	18 / 274 (6.57%) 21	
Gastrointestinal disorders ABDOMINAL PAIN UPPER subjects affected / exposed occurrences (all)	15 / 291 (5.15%) 20	5 / 274 (1.82%) 7	
CONSTIPATION subjects affected / exposed occurrences (all)	92 / 291 (31.62%) 104	79 / 274 (28.83%) 96	
DIARRHOEA subjects affected / exposed occurrences (all)	60 / 291 (20.62%) 88	47 / 274 (17.15%) 56	
DYSPEPSIA subjects affected / exposed occurrences (all)	16 / 291 (5.50%) 18	9 / 274 (3.28%) 10	
NAUSEA subjects affected / exposed occurrences (all)	112 / 291 (38.49%) 266	114 / 274 (41.61%) 206	
STOMATITIS subjects affected / exposed occurrences (all)	35 / 291 (12.03%) 45	23 / 274 (8.39%) 26	
VOMITING subjects affected / exposed occurrences (all)	58 / 291 (19.93%) 81	49 / 274 (17.88%) 64	
Skin and subcutaneous tissue disorders PRURITUS subjects affected / exposed occurrences (all)	29 / 291 (9.97%) 37	16 / 274 (5.84%) 17	
DRY SKIN subjects affected / exposed occurrences (all)	20 / 291 (6.87%) 23	7 / 274 (2.55%) 7	
RASH			

subjects affected / exposed occurrences (all)	41 / 291 (14.09%) 54	21 / 274 (7.66%) 23	
Endocrine disorders HYPOTHYROIDISM subjects affected / exposed occurrences (all)	18 / 291 (6.19%) 19	2 / 274 (0.73%) 2	
Musculoskeletal and connective tissue disorders ARTHRALGIA subjects affected / exposed occurrences (all) BACK PAIN subjects affected / exposed occurrences (all) PAIN IN EXTREMITY subjects affected / exposed occurrences (all)	46 / 291 (15.81%) 61 40 / 291 (13.75%) 51 23 / 291 (7.90%) 23	26 / 274 (9.49%) 29 25 / 274 (9.12%) 28 13 / 274 (4.74%) 13	
Infections and infestations UPPER RESPIRATORY TRACT INFECTION subjects affected / exposed occurrences (all) CONJUNCTIVITIS subjects affected / exposed occurrences (all) NASOPHARYNGITIS subjects affected / exposed occurrences (all) PNEUMONIA subjects affected / exposed occurrences (all)	16 / 291 (5.50%) 22 18 / 291 (6.19%) 23 15 / 291 (5.15%) 20 16 / 291 (5.50%) 20	10 / 274 (3.65%) 13 15 / 274 (5.47%) 18 8 / 274 (2.92%) 10 11 / 274 (4.01%) 12	
Metabolism and nutrition disorders DECREASED APPETITE subjects affected / exposed occurrences (all) HYPERGLYCAEMIA subjects affected / exposed occurrences (all)	78 / 291 (26.80%) 101 15 / 291 (5.15%) 17	64 / 274 (23.36%) 84 17 / 274 (6.20%) 20	

HYPOKALAEMIA			
subjects affected / exposed	21 / 291 (7.22%)	4 / 274 (1.46%)	
occurrences (all)	29	4	
HYPOMAGNESAEMIA			
subjects affected / exposed	19 / 291 (6.53%)	14 / 274 (5.11%)	
occurrences (all)	31	19	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
24 November 2015	Protocol was amended to change OS rate at 3 years from Secondary Efficacy Objective to Exploratory Outcome Measure. Exclusion Criteria Treatment with systemic immunostimulatory agents within 4 weeks prior to randomization updated to include or 5 half-lives of the drug, whichever is longer.
09 June 2016	Protocol was amended to change the assessment of the patients for the objectives to chemotherapy-naïve and have stage IV non-squamous NSCLC (the ITT population) treated with atezolizumab + carboplatin or cisplatin + pemetrexed (Arm A) in comparison to carboplatin or cisplatin + pemetrexed (Arm B). Previous primary efficacy objectives were removed with the exception of investigator-assessed PFS and OS was added. Secondary Efficacy Objectives were updated with the change in patient assessment. Secondary Efficacy Objective investigator-assessed PFS replaced with IRF-assessed PFS. Time to response added to Secondary Efficacy Objective. "Patients with a sensitizing mutation in the EGFR gene or an ALK fusion oncogene" added to cancer specific exclusion criteria. "Or cerebrovascular accident" added to "Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomization, unstable arrhythmias, or unstable angina." General Medical Exclusions. "Illness or condition that may interfere with a patient's capacity to understand, follow, and/or comply with study procedures" added to General Medical Exclusions. "Prior treatment with EGFR inhibitors or ALK inhibitors" added to Exclusion Criteria Related to Medications. Exclusion Criteria Related to Medications updated with "Any approved anti-cancer therapy, including hormonal therapy within 21 days prior to initiation of study treatment".
09 October 2017	Protocol was amended to remove all objectives and outcome measures based on review by IRF. Secondary efficacy objective and outcome measure for SILC scale symptom severity scores has been updated so that it will be measured from baseline instead of time to deterioration (TTD).
02 November 2018	Protocol was amended to correct the end of study definition. This correction ensures that the study continues until last patient, last visit or until the Sponsor terminates the study. The contraception requirement for female patients has been clarified and text has been added to specify when women must refrain from donating eggs. The list of risks associated with atezolizumab has been revised to align with current atezolizumab risk language, and guidelines for managing patients who experience atezolizumab-associated adverse events have been revised to include nephritis.
11 February 2020	Protocol was amended to include myositis to the list of atezolizumab risks for consistency with the list of identified risks in the Atezolizumab Investigator's Brochure.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported